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Abstract: Increasing evidence suggests that neurodegenerative disorders share a common pathogenic
feature: the presence of deposits of misfolded proteins with altered physicochemical properties
in the Central Nervous System. Despite a lack of infectivity, experimental data show that the
replication and propagation of neurodegenerative disease-related proteins including amyloid-β (Aβ),
tau, α-synuclein and the transactive response DNA-binding protein of 43 kDa (TDP-43) share a
similar pathological mechanism with prions. These observations have led to the terminology of
“prion-like” to distinguish between conditions with noninfectious characteristics but similarities with
the prion replication and propagation process. Prions are considered to adapt their conformation
to changes in the context of the environment of replication. This process is known as either prion
selection or adaptation, where a distinct conformer present in the initial prion population with
higher propensity to propagate in the new environment is able to prevail over the others during the
replication process. In the last years, many studies have shown that prion-like proteins share not only
the prion replication paradigm but also the specific ability to aggregate in different conformations,
i.e., strains, with relevant clinical, diagnostic and therapeutic implications. This review focuses on the
molecular basis of the strain phenomenon in prion and prion-like proteins.
Keywords: prion; prion-like proteins; strains; neurodegeneration
1. Introduction
Neurodegenerative diseases (NDDs) are characterized by the progressive dysfunction and loss
of specific neurons leading to the irreversible damage of functional circuitry, ultimately defining
their clinical presentations. NDDs include Alzheimer’s disease (AD), Parkinson’s disease (PD),
amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), prion diseases or Transmissible
Spongiform Encephalopathies (TSEs) and many others. Although they differ in terms of clinical
and neuropathological features, increasing evidence suggests that these disorders share a common
pathogenic feature: the presence of deposits of misfolded proteins with altered physicochemical
properties in the Central Nervous System (CNS) [1]. Thus, a classification of NDDs is based according
to the predominant protein that is deposited in the brain, leading to the definition of proteinopathies
or conformational diseases [2]. The main protein component of these pathological deposits may be
unique for each disorder, e.g., α-synuclein in Parkinson’s disease (PD), while in other conditions more
than one misfolded protein can be involved [1]. Extracellular deposits comprise aggregates with an
immunoreactivity for amyloid-β (Aβ) or prion protein (PrP), while proteins found in intracellular
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deposits include tau, α-synuclein and TAR DNA-binding protein 43 (TDP-43). These proteins associate
with sporadic and inherited forms, while in the case of prion protein, an infectious route of transmission
is also possible.
To date, prion diseases are the unique neurodegenerative disorders showing an infectious
transmissible protein species capable of recapitulating a clinical disease [3,4] with no clear evidence to
the naturally occurring human-to-human transmission of other neurodegenerative conditions [5,6].
Despite this observed lack of infectivity, the high degree of misfolded protein deposition and
experimental evidence showing the replication and propagation of various other neurodegeneration
related proteins—including Aβ, tau, α-synuclein and TDP-43—suggests that these neurodegenerative
diseases share a similar pathological mechanism with prions. These observations have led to the
terminology of “prion-like” to distinguish between conditions with noninfectious characteristics and
to compare similarities with the prion replication and propagation process [7] (Figure 1). The canonical
model for the aggregation of misfolded proteins is based on the prion paradigm [8,9]. According
to the “protein-only” hypothesis formulated in 1980 by Stanley B. Prusiner, which coined the term
“prion” (proteinaceous infectious particle) [10], the critical pathological step in prion disorders is the
conversion of the normal cellular prion protein (PrPC) into a β-sheet-enriched pathological conformer
PrP-scrapie (PrPSc). The term scrapie derives from the name of a TSE which affects sheep and goats.
Even if PrPSc possesses the same amino acidic sequence of PrPC, it acquires specific features that
differentiate it from its normal counterpart, like a partial resistance to digestion with proteinase K (PK),
an insolubility in nonionic detergents and the enrichment in β-sheet content. PrPSc is able to induce
other PrPC molecules to misfold and aggregate into small oligomers, protofibrils and amyloid fibrils,
leading to the pathological process [8,11].
Misfolded protein assemblies in NDDs have been shown to act as seeds of aggregation that can
sequester their native isoforms and convert into pathological molecules, thereby growing in size. The
term “seed” indicates the smallest amount of a misfolded protein able to template the pathological
conversion onto native molecules. The subsequent fragmentation of the aggregates and the repetition
of the cycle leads to the amplification of the pathological state within one cell, as well as through the
nervous system via the release of seeds to the extracellular space, via the uptake by the neighboring
cells and via the repetition of the propagation cycle [2]. According to this concept, a misfolded protein
is considered to display prion-like properties if it possesses seeding properties, if it is able to spread
and propagate, if it can form structurally unique strains and, finally, if the protein aggregates induce
neurotoxicity [4]. Among all the peculiar features of prions, one of the most intriguing is the prion
strain phenomenon. Animals affected by prion diseases may develop different pathologies with unique
clinical and biochemical outcomes that can be maintained through passages in animals. Prions, thus,
are not homogeneous isomorphic particles but rather comprise a mixed population of PrP assemblies
that share the ability to structurally convert other PrP molecules [9].
Prions are now considered to be able to adapt their conformation to changes in the context of
the environment of replication [12–14], and studies on synthetic prions [15,16] revealed that this
phenomenon is replicated not only in animal models but also in vitro in cells. This process is known
as either prion selection or adaptation, where a distinct PrPSc conformer present in the initial prion
population with a higher propensity to propagate in the new environment is able to prevail over the
others during the replication process [12] (Figure 2). Increasing evidence is suggesting that prion-like
proteins such as Aβ, α-synuclein, tau and TDP-43 share not only the prion replication paradigm but
also this specific ability to aggregate in different conformations, i.e., strains [17–21], with relevant
clinical, diagnostic and therapeutic implications.
Familial AD patients with mutations in the Aβ precursor protein (APP) gene tested negative
for the amyloid-specific positron emission tomography (PET) probe, Pittsburgh compound B (PiB),
which is commonly used to detect Aβ deposits in sporadic AD (sAD) cases [22], despite showing a
severe cerebral amyloid burden in postmortem analysis [23], suggesting the presence of a structural
difference between Aβ deposits in these subjects when compared to sporadic patients [24,25]. Several
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studies have shown the presence of different Aβ conformers in amyloid deposits not only in subjects
harboring an APP gene mutation but also in patients with different AD clinical subtypes [19–21].
Similarly, it has been showed that tau strains derived from distinct human tauopathies are propagated
in vivo through intracranial injections into wild-type mice and transgenic mouse models of AD; these
pathologies closely recapitulate distinct features of human AD and its associated tauopathies [18].
Moreover, it is currently hypothesized that under specific disease conditions, endogenous α-synuclein
assemblies aberrantly fold to form prion strains [26–28] and that, after exogenous administration,
pathogenic α-synuclein inflicts pathology by amplifying in a permissive environment via different
routes [27,29–31]. A deep understanding of the molecular basis leading to the strain formation and
propagation could be of utmost relevance to carefully approach, to classify and, ultimately and
hopefully, to cure different entities belonging to the same neurodegenerative disorder. In this context,
these diseases could be better addressed as “conformational disorders” instead of the more generic
definition of proteinopathies. Given the relevance of this topic, this review will highlight the evidence
pointing to the existence of prion and prion-like protein strains, starting from the well-established
notions about the prion protein and subsequently moving to the emerging data regarding the other
prion-like proteins involved in neurodegeneration.
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Figure 1. A schematic illustration of the prion-like characteristics of aggregated proteins: (A) Once 
they have entered healthy neurons, amyloids (red hexagons) interact with their native counterparts 
(blue circles) and act as a template to seed their misfolding. The process is self-amplifying and leads 
to the formation of long fibrillar aggregates which are transported along the axons toward synaptic 
terminals. (B) The aggregates spread to neighbouring cells via multiple mechanisms, many of which 
require an active regulation by the cell itself. (1) Endocytosis: Prion-like proteins (synuclein) exploit 
membrane receptors (LAG3 [32] and prion protein [33]) or clathrin-dependent endocytosis (tau) to 
enter the cell cytoplasm. (2) Tunneling nanotubes (TNTs): TNTs are involved in the spreading of tau, 
prions, synuclein and Aβ [34]. (3) Exosomes: Exosomes have been found to be implicated in the 
spreading of pathological protein aggregates [35]. (4) Macropinocytosis: The tau protein is transferred 
through macropinocytosis mediated by heparin sulfate proteoglycans [36]. 
Figure 1. A schematic illustration of the prion-like characteristics of aggregated proteins: (A) Once
they have entered healthy neurons, amyloids (red hexagons) interact with their native counterparts
(blue circles) and act as a template to seed their isfolding. The process is self-amplifying and leads
to the formation f l ng fibrillar ag regates i re transported along the axons toward synaptic
terminals. (B) The aggregates spread to neig i g cells via multiple mechanis s, many of which
require an active regulation by the cell itself. (1) cytosis: Prion-like proteins (synucl in) exploit
membrane receptors (LAG3 [32] and prion protein [33]) or clathrin-dependent endocytosis (tau) to
enter the cell cytoplasm. (2) Tunneling nanotubes (TNTs): TNTs are involved in the spreading of
tau, prions, synuclein and Aβ [34]. (3) Exosomes: Exosomes have been found to be implicated in the
spreading of pathological protein aggregates [35]. (4) Macropinocytosis: The tau protein is transferred
through macropinocytosis mediated by heparin sulfate proteoglycans [36].
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Figure 2. The p ion and prion-like strain sel cti or adaptation: (A) Acc rding to the replication
environment, one prion or prion-like species (i.e., red square in human, yellow diamond in cattle
and blue triangle in vitro) present in the initial prion strain population can prevail on the others
and be selectively amplified. This phenom no c uld manifest in vivo in different a imal species,
probably influenced by differences in the PrPC sequence of the host, or in vitro according to different
experimental settings. (B) The appearance of a new prion or prion-like strain can depend on the
mechanism of adaptation. In this scenario, one conformer already present in the initial strain population
can change its conformation, adapting to the host environment (e.g., blue triangle transforms into
yellow diamond). This phenomenon could also explain how prions escape the species barrier. These
two processes are not mutually exclusive.
2. Prion Protein
2.1. The Cellular Prion Protein
The cellular prion protein, PrPC, is a glycosylphosphatidylinositol (GPI)-anchored protein of 231
amino acids encoded by the PRNP gene located on chromosome 20 in humans and on chromosome
2 in mice [37–41]. Its sequence can be divided into two structurally well-defined regions: a long,
N-terminal flexible tail containing series of four or five repeats of eight amino acids (PHGGGWGQ)
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and a globular C-terminal domain containing 3 α-helices and 3 β-strands, 2 of which flank the first
α-helix. As a typical cell-surface glycoprotein, the pre-pro-protein is translocated to the endoplasmic
reticulum (ER) where it is subjected to several posttranslational modifications including the N-linked
glycosylation at residues N181 and N197 in humans, the formation of a single disulfide bond at
position C179 and C214, the cleavage of the C-terminal signal peptide and the subsequent attachment
of the glycosylphosphatidyl inositol (GPI) anchor at position 231 [42]. PrPC is widely expressed in the
CNS during early development and in adult neurons and glial cells. In the adult brain, maximal PRNP
mRNA expression is observed in the neocortex and cerebellum. In addition to the nervous system, the
mammalian expression of PrPC has been reported in several tissues including lymphoid organs and
the heart [40,43,44] and at lower levels in the kidney and liver [44,45]. Even if the PrPC physiological
role is far from being completely understood, several putative functions have been suggested for PrPC,
including neuritogenesis, neuronal homeostasis, cell signaling, cell adhesion and a protective role
against stress [46]. In humans, prion disorders or TSEs include idiopathic forms such as sporadic
Creutzfeldt-Jakob disease (sCJD), sporadic fatal insomnia (sFI) and the variably proteinase sensitive
prionopathies (VPSPr). Familial CJD (fCJD), Gerstmann–Sträussler–Scheinker disease (GSS), fatal
familial insomnia (FFI) and prion protein cerebral amyloid angiopathy (PrP-CAA) are genetic forms of
human TSEs. The acquired forms are transmitted from human to human as iatrogenic CJD (iCJD) and
Kuru or from cattle to human as variant CJD (vCJD) [47]. In animals, TSEs include scrapie in sheep
and goats, bovine spongiform encephalopathy (BSE) in cattle and chronic wasting disease (CWD) in
cervids [48].
2.2. Molecular Basis of Prion Strains
Stanley B. Prusiner elegantly and unambiguously showed that the scrapie infectious agent was
a proteinaceous particle devoid of nucleic acids. Pattison and Millson [49] had already observed the
existence of different prion strains in goats. In their reports, they described two different clinical
phenotypes in goats affected by the same batch of the scrapie agent. The authors called these
phenotypes “scratching” and “nervous” syndromes according to the main clinical manifestations of
the animals. Even if they were not aware of the nature of the infectious agent, they clearly recognized
that the two syndromes were reproducible by the intracerebral inoculation of animals, suggesting
that certain "strains" of the scrapie agent produced the nervous syndrome, while others produced
the scratching one [49]. In microbiology, a strain is defined as an isolate or group of isolates that can
be distinguished from other isolates of the same genus and species by phenotypic characteristics or
genotypic characteristics or both [50]. Since the nature of the scrapie infectious agent was unknown, the
description of the scrapie strains initially seemed to be an indirect proof for the existence of a different
genetic information encoded by a specific scrapie-causing agent, thus conflicting with the protein-only
hypothesis. However, using different approaches, including Fourier transform infrared spectroscopy
(FTIR), atomic force microscopy (AFM) and circular dichroism (CD), it has been shown that differences
in prion strains lie in the different conformations of PrPSc [51–56]. Prion strains can be classified
according to different parameters, which can be divided in two main groups, mutually related one to
the other: in vivo characteristics [57–59] and biochemical properties of the infectious protein [52,60–63].
The most commonly used in vivo criteria for the classification of a given prion strain are the incubation
period, which is defined as the time elapsed between an experimental inoculation of a given dose
and the clinical onset of disease; the survival time; and the main clinical signs (e.g., rough coat, ataxia
and loss of weight) [13]. Other parameters for the in vivo strain classification are neuropathological
differences in terms of the preferential distribution of PrPSc deposition in the CNS (e.g., synaptic,
peri-neuronal, plaque-like and amyloid plaques) and the degree of vacuolation in specific brain regions
of the affected animal [12,64–67]. In order to quantify these aspects, a standardized procedure in mice,
called lesion profile, for the scoring of vacuolization in a number of gray matter and white matter brain
areas (depending on the scoring system used) of the affected animal has been developed [13]. The
most relevant biochemical properties of the infectious protein appreciated in different prion strains are
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the electrophoretic mobility after PK digestion, the glycosylation pattern (i.e., the prevalence of the
mono- or di-glycosylated form), the extent of PK resistance and sedimentation, and the resistance to
denaturation by a chaotropic agent [13,52,60–63].
2.3. Strain Diversity in Human TSEs
PrPSc strains are considered to be at the basis of the wide variability of human TSEs in terms
of clinical signs, incubation periods, neuropathological manifestations and biochemical properties
of the deposited PrPSc. Since human prion disorders are characterized by a plethora of possible
manifestations that appear with more or less intensity depending on the strain of the agent causing
the disorder, clinical signs represent a powerful guide to discriminate between different entities. For
example, sCJD patients usually present with cognitive decline, ataxia or visual disturbance either alone
or in combination [68,69], while vCJD cases are caused by the transmission of BSE to humans; often
psychiatric symptoms prevail, usually preceding neurological signs [70]. In other genetic forms of
human TSEs, like FFI, subjects experience the inability to initiate and maintain sleep, with frequent
arousals and enacted dreams associated with autonomic alterations [71]. Intriguingly, to complicate
even more the variety of clinical manifestations linked to prion agents, different groups reported
familial cases of prion disorders linked to the genetic mutations in the PRNP gene and characterized
by severe chronic diarrhea and autonomic alterations in the apparent absence of the involvement
of the CNS [72].The different nature of the biochemical features of PrPSc in several subtypes of
sCJD and in the sporadic form of fatal insomnia (sFI) led to a classification system based on two
distinct patterns of electrophoretic mobility of the unglycosylated protease-resistant fragment of
PrPSc (type 1 and 2) and on the associated genetic polymorphism at codon 129 of the PRNP gene
(methionine or valine; MM, MV and VV) [69]. Furthermore, Western blot (WB) patterns depend on
the PK cleavage of PrPSc at different sites resulting in type 1 when the unglycosylated PK-resistant
fragment presents a molecular mass of 21 kDa and in type 2 when it has a molecular mass of 19 kDa
(Figure 3A) [69]. Interestingly, this classification shows a strong correlation between the clinical
phenotype, the neuropathological features of PrPSc deposition and the biochemical and structural
properties of the specific strain of the deposited PrPSc, thus giving a strain-related explanation of the
extreme clinical heterogeneity of sCJD. Further evidence providing a correlation between the specific
pathologic phenotypes and the structural and biochemical features of PrPSc in human prion disorders
derives from the demonstration that what distinguishes the genetic of FFI to a specific familial form
of CJD (fCJD178) is the genotype at the polymorphic codon 129 in the allele of the PRNP gene which
contains the same pathogenic point mutation at codon 178. In fact, FFI is an autosomal dominant
prion disorder linked to a mutation in codon 178 of the PRNP gene, resulting in the substitution of
aspartic acid with asparagine (D178N); however, the same mutation is also linked to fCJD178, but in
FFI, the D178N mutation is aligned with methionine at codon 129 (D178N-129M haplotype), while in
fCJD178, there is valine (D178N-129V haplotype) [73]. This proves that the 129M/V polymorphism
associated with a single mutation can determine different phenotypes. Furthermore, WB analyses
showed that the PK-resistant PrPSc has a different electrophoretic mobility in these two disorders,
having the unglycosylated band at an electrophoretic mobility of 19 kDa in FFI and of 21 kDa in
fCJD178 [74]. Further complicating this scenario is the existence of a sporadic form of fatal insomnia
(sFI) not related to any mutation in the PRNP gene but displays overlapping clinical features and the
same PK-resistant PrPSc electrophoretic mobility pattern of FFI, thus suggesting that a similar prion
strain is responsible for these two disorders [69].
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Figure 3. Representative western blot profiles of the prion and prion-like pathological proteins extracted
from diseased brains: (A) A schematic representat on of human PrPSc types after PK digestion. In the
sCJD cases, the PK cleavage of PrPSc results in type 1 when the unglycosylated PK-resistant fragment
presents a molecular mass of 21 kDa and in type 2A when the it has a molecular mass of 19 kDa. In
both cases, there is a predominance of the mono-glycosylated band over the others. vCJD presents
a different pattern associate with the presence of the unglycosylated PK-resistant fragment of 19
kDa and the predominanc of th di-glycosylated band in the glycoform atio (type 2B). (B) The four
different electrophoretic patterns of pathological tau proteins are composed of bands at 60, 64, 69 and
74 kDa, which correspond to the pathological tau that are found in aggregates in different tauopathies
(listed on the top of each pattern). (C) The representative immunoblots with the phosphorylated
TDP-43 specific antibody, S409/410. FTLD-TDP type B pathology shows three major bands at 23, 24
and 26 kDa and two minor bands at 18 and 19 kDa, with the predominance of the 24 kDa band. Type C
pathology shows two major bands at 23 and 24 kDa and two minor bands at 18 and 19 kDa with the 23
kDa band being the most represented. Type A pathology is not distinctive but intermediate between
the other two. sCJD: sporadic Creutzfeldt-Jakob disease; vCJD: variant Creutzfeldt-Jakob disease; AD:
Alzheimer’s Disease; PSP: Progressive Supranuclear Palsy; CBD: Corticobasal Degeneration; AGD:
Argirophilic Grain Disease; FTLD-17: Frontotemporal Dementia linked to chromosome 17; PiD: Pick’s
Disease; DM: myotonic dystrophy; bvFTD: behavioural variant of Frontotemporal Dementia; naPPA:
nonfluent/agrammatic primary progressive aphasia; MND: motor neuron disorder; svPPA: semantic
variant primary progressive aphasia.
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2.4. Species Barrier, Prion Strains Transmission, Selection and Adaptation
Since a strain is defined through its clinical, neuropathological and structural properties, the
use of animal models has been instrumental to further characterize and define prions. Among all
experimental animal models, mice have discriminated more than 20 different prion strains so far [13].
Strain isolation is usually obtained through the inoculation of scrapie-infected material from goat and
sheep, BSE-derived material from cattle or human sources of PrPSc from the brains of deceased subjects
with sCJD or GSS [65,66,75–78]. Usually, in order to obtain a stabilized strain, several passages of the
same source in one species with a constant background are needed. Examples of mouse-adapted scrapie
prion strains are RML, ME7, 139A and 79A, while mouse strains generated by the inoculation of BSE
and sCJD prions are the 301C and Fukuoka, respectively [79–81]. Interestingly, the agent responsible
for prion disorders seems to be able to infect some animal species and not others. This phenomenon,
known as “species barrier” depends mainly on genetic variability and on sequence difference of PrPC
in the host animal and explains the prolongation in the incubation period observed [82,83]. When the
PrPC host structure is completely resistant to prion infection, the species barrier is considered absolute.
One example of an absolute species barrier is the rabbit, which has been classified as TSE-resistant
for four decades, until 2012, when this absolute barrier was overcome with the use of in vitro prion
amplification using the technique Protein Misfolding Cyclic Amplification (PMCA) (see next Section),
demonstrating the transmissibility of the amplified product in 2 out of 10 rabbits, which can no longer
be considered as completely resistant to prions [84].
The only known prion agent capable of transmission between animals and humans is BSE, and
it is currently accepted that the consumption of BSE-infected products is the cause of vCJD [85,86].
Transmission studies had a crucial role in establishing a causal link between BSE and vCJD. BSE and
vCJD had similar incubation periods and lesion profiles in infected mice brains, which were distinct
from those of both scrapie and sCJD [87]. vCJD PrPSc displays peculiar biochemical properties
characterized by the presence of the unglycosylated PK-resistant fragment of 19 kDa and the
predominance of the di-glycosylated band [88]. Clinically, vCJD differs from all other human prion
disorders, being characterized by early and persistent psychiatric symptoms and followed, after some
months, by neurological signs [89]. Intriguingly, until 2017 [90], all probable/definite vCJD-reported
cases were homozygous for methionine (MM) at codon 129 of the PRNP gene, thus, suggesting an
absolute barrier displayed by a PrPC sequence associated with MV or VV genotype (i.e., no clinically
affected subjects were MV or VV carriers). In 2017, the first case of an affected subject harboring the MV
genotype which displayed typical vCJD neuropathological and biological features was described [90].
Furthermore, a biochemical analysis of the spleen of asymptomatic MV subjects which received a blood
donation from vCJD donors [91,92] showed the presence of pathological prion protein deposition,
which, in one case, displayed also infectivity when injected in mice [91]. These studies demonstrated
that spleen tissue from an asymptomatic PRNP MV genotype subject can propagate the vCJD disease
agent and that the infectious protein can be present in the spleen without CNS involvement.
Altogether, these data created surveillance concerns regarding the presence in the population
of MV subjects with subclinical vCJD. Furthermore, an elegant study conducted on a large cohort of
nonhuman primates showed that vCJD infectious agent(s) contained in soluble or insoluble fractions of
vCJD blood donors is/are able to replicate in macaques generating typical and nonconventional vCJD
phenotypes, the latter characterized by the presence of PK-sensitive PrPSc deposition and atypical
clinical features mainly involving the spinal cord [93]. These results clearly open several questions
regarding the design of appropriate vCJD surveillance protocols. The appearance of new prion
strains after infection with the same source of PrPSc suggests that prions are able to modify their
conformation to changes in the context of replication: This ability may derive from the adaptation
of the prion pathological structure to a new environment or from the selection of a single prion
species, which prevails under specific replication conditions (Figure 2) [12,13]. One clear example
of this phenomenon is the isolation of two different prion strains after the inoculation of a Syrian
hamster with the transmissible mink encephalopathy (TME) agent [57]. This interspecies transmission
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of prions presented the expected behavior of the species barrier phenomenon: a long incubation
period after the first infection followed by a shorter incubation periods after several passages. The
incubation intervals became stable in two groups of animals with different clinical manifestations:
the first one with an incubation period of approx. 150 days postinoculation (dpi) presented lethargy
(DY), while a shorter incubation period strain (approx. 60 dpi) presented hyperactivity (HY) [57]. A
biochemical and histological analysis of the CNS showed that the PrPSc of the two groups possessed
different electrophoretic mobilities, a distinct resistance to PK digestion and stability against guanidine
hydrochloride and induced different neuropathological alterations [51,60,94].
These observations suggest two possible hypothesis: in the first one, the infectious strain exists
as a single structural species and the appearance of a new one derives from a sort of mutation that
occurred during the replication process (i.e., adaptation); in the second one, the infectious strain
is composed by a population of different conformers with a dominant type of PrPSc preferentially
replicating in a specific host, and in another one, a different subtype prevails (i.e., selection) according
to the new replication environment (Figure 2). Although this phenomenon is still not completely
understood, the DY and HY example provided direct evidence of the ability of prions to undergo
the process of adaptation or selection according to the environment of replication (mink vs. hamster
CNS). Furthermore, it has been shown that brain-derived prion strains replicating in cell cultures can
evolve following a Darwinian model when exposed to a drug-dependent selective pressure [95]. The
high impact of the prion strain phenomenon on therapeutic drug efficacy and, thus, development was
confirmed in another elegant study which demonstrated that prion strains can acquire resistance upon
exposure to a specific anti-prion compound (called IND24) and that this resistance is lost upon passage
in mice not exposed to the molecule [96]. The advent of synthetic prions [15,16] enabled the study of
the prion-strain phenomenon in a highly pure and reproducible environment, providing a powerful
tool for the study of this process.
2.5. Synthetic Prion Strains
As stated before, conversely to PrPC, PrPSc is rich in β-sheet structures and its partial proteolytic
digestion leads to the formation of a PK-resistant core, PrPres. In most cases, in vitro-generated
PrPres failed to induce any prion pathology after inoculation in susceptible animals, suggesting that
the acquisition of proteinase resistance was not enough for the propagation of infectivity [97–100].
Intracerebral inoculation into transgenic mice expressing the mutant PrP (P101L) using a synthetic
PrP peptide carrying the homologous P101L pathogenic mutation and forced to refold in β-sheet
structures induced prion disease after about 200 dpi [101,102]. This disease was not transmissible
to wild-type animals. Pathological alterations were not observed when the injection was performed
with peptides harboring the same sequence but lacking the β-sheet structures [103]. In another
set of experiments, recombinant PrP (recPrP) was induced to misfold and acquired two different
conformations: β-oligomers (in the presence of acidic pH and urea) or fibrillar structures (neutral pH
and low concentration of urea) [98]. This reaction was also performed in the presence (seeded) or in
the absence (unseeded) of recPrP-preformed amyloid aggregates, and then, the seeded and unseeded
products where assessed for infectivity by intracerebral inoculation in transgenic mice (Tg9949)
overexpressing the N-terminally truncated mouse PrP (residues 89–230). In both cases, the animals
succumbed to prion disease but with different neuropathological alterations [16]. Specifically, animals
treated with the seeded product exhibited a shorter incubation time associated with higher PrPres
deposition in the CNS. The isolate collected from those animals was called MoSP1 and was passaged
to wild-type mice which were efficiently infected and showed the presence of PrPres deposition in their
brains [16]. These results provided relevant information about the relationship between the stability
of a specific prion isolate and the length of incubation time after inoculation in susceptible animals,
which showed to be directly correlated [15,104].
In order to better characterize the relationship between conformation, stability and infectivity,
several laboratories started to produce synthetic prions showing that not all the obtained amyloids
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were infectious and those which were infectious induced neuropathological changes characterized
by a unique pattern of PrP deposition, revealing that each inoculum was a unique isolate and that
the properties of this isolate relied on its specific sequence and structure [46]. Recently, one group
reported the synthesis of another human prion strain derived from the in vitro aggregation of human
recombinant non-glycosylated prion protein seeded with sCJD MM1 prions, using ganglioside GM1
as a cofactor [105]. These synthetic human prions were infectious to transgenic mice expressing
non-glycosylated human prion proteins, causing neurologic dysfunction after 459 and 224 days in the
first and second passage, respectively. These results confirmed that prion infectivity, host range and the
ability to target specific mice brain structures could be related to changes in the structural organization
of critical domains, some linked to posttranslational modifications of the pathogenic prion protein
(PrPSc). As mentioned above, synthetic prion strains offered as useful tools to decipher the prion
selection and adaptation phenomena. When the MoSP1 strain was serially transmitted to wild-type
mice, at least two different prion isolates were observed, namely MoSP1(1) and MoSP1(2) [106,107].
Both strains were characterized by two different molecular masses of the PK-resistant core, 21 and 19
kDa, respectively [108].
Another strategy to a generate synthetic prion was based on the PMCA technique [109]. In
this case, infectious PrPSc is mixed with an excess of PrPC. Cycles of incubation and sonication are
repeated several times. The sonication disaggregates PrPSc fibrils, thus generating different seeds
that can recruit and convert normal PrPC. After several rounds of PMCA using recPrP that has never
been exposed to any prion, a de novo generation of PrPres was observed. In particular, two types of
self-perpetuating PrPres characterized by two different PK-resistant cores of 17 and 14 kDa, respectively,
were generated [110]. However, only the PrPres of 17 kDa was highly infectious to mice. PMCA has
also been exploited to assess different aspects of prion diseases, including the species barrier and
the strain adaptation phenomena [84,111–113]. Recently, our group showed the ability of a synthetic
mouse prion previously generated [114] to change its biochemical properties when challenged in vivo
or in vitro by means of PMCA. In vivo experiments revealed that after the serial transmission passages,
it was possible to identify two distinct conformations of PrPSc. One of these conformations was
characterized by a prevalence of the di-glycosylated isoform of PrPSc (PrPSc-D), while the other
was characterized by the prevalence of the mono-glycosylated isoform (PrPSc-M). Both abnormal
conformations were associated with distinct clinical, biochemical and neuropathological alterations.
A PMCA analysis of PrPSc-D and PrPSc-M revealed that, regardless of the inoculum, the amplified
product was characterized by a prevalence of the di-glycosylated form of PrP (PrPSc-PMCA) [12].
These data suggest that the synthetic prions can adapt their conformation according to changes of the
context of replication.
3. Amyloid-β
3.1. Amyloid-β Peptide Formation, Alzheimer’s Disease and Its Atypical Variants
Alzheimer’s disease (AD) is characterized by the accumulation of the amyloid-β peptide (Aβ)
within the brain, associated with the deposition of hyperphosphorylated and cleaved forms of the
microtubule-associated protein tau. Compelling evidence suggests that physiologic generation of the
neurotoxic Aβ peptide from the sequential cleavage of the much larger transmembrane protein amyloid
precursor protein (APP) is the crucial step in the development of AD [115,116]. The APP gene is located
on chromosome 21, and the protein product is a member of a family of related proteins that includes the
amyloid precursor protein-like APLP1 and APLP2, which are all single-pass transmembrane proteins
with a large extracellular domain and are all processed in a similar manner [116]. Despite many roles
being suggested for APP [116], its precise physiological function is not known and remains a relevant
unanswered issue in deciphering AD pathology.
The complete deletion of APP in mice (and of Aβ formation) produces very little phenotype
modifications, thus suggesting that a loss of APP or Aβ function is not deleterious [116]. The
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N-terminus of Aβ is located in the extracellular domain of APP, 28 amino acids from the transmembrane
region, while its C-terminus is located in the transmembrane region. The enzymes responsible for
cleavage at the N- and C-termini are called β-secretase, or β-site amyloid precursor protein cleaving
enzyme 1 (BACE1), and γ-secretase, respectively. The latter is a multiprotein complex composed
of presenilin 1 (PS1) or presenilin 2 (PS2) and other transmembrane proteins [117]. A third enzyme
α-secretase cleaves between residues 16 and 17, precluding Aβ formation [115]. In fact, APP can
be proteolyzed by α-secretase and then γ-secretase, a process that does not generate Aβ, or can be
internalized into clathrin-coated vesicles and then cleaved by β-secretase and γ-secretase. The latter
process results in the production of Aβ, which is then released into the extracellular space. Following
BACE1 cleavage, the APP C-terminal fragment is cleaved by the γ-secretase complex at one of several
sites varying from +40 to +44 to generate Aβ peptides (1–40 and 1–42 being most common) and the
APP intracellular domain [116]. There are 32 APP, 179 PSEN1 (presenilin 1 gene locus) and 14 PSEN2
gene mutations that result in early onset, autosomal dominant, fully penetrant AD. The common
thread to all these mutations is that they increase the production of the less soluble and more toxic
Aβ42 relative to Aβ40 species [118].
In Down’s syndrome, the overexpression of APP results in Aβ deposition in the brain when
individuals are in their late twenties. Neurofibrillary tangles develop later and correlate with the onset
of the midlife cognitive decline that is common in these individuals [119]. The risk for developing
late-onset AD is related to the presence of the apolipoprotein E (APOE) E4 allele which increases
the risk for AD to three-fold in individuals carrying one copy of it and to 15-fold in homozygous
subjects [116].
The typical AD dementia syndrome has at its clinical core, an amnestic syndrome of the
hippocampal type, followed by deficits in word-finding, spatial cognition, executive functions and
neuropsychiatric changes [120]. In addition to its typical presentation, non-amnestic atypical variants
of AD have been described [121]. Atypical presentations of AD include posterior cortical atrophy
(PCA), logopenic progressive aphasia (LPA) and the frontal variant of AD (fvAD). In PCA, the onset
is characterized by early, higher-order visual deficits with a higher deposition of neurofibrillary
tangles in the occipital regions than in typical AD. LPA is an atypical language variant defined as a
primary phonological loop deficit leading to impaired memory, sentence repetition and comprehension,
with sparse spontaneous speech and frequent prolonged word-finding pauses. Greater numbers of
neurofibrillary tangles within the frontal lobes are seen in fvAD, resulting in a more severe disease
course characterized by early behavioral alterations and executive dysfunction [120]. Recently, some
cases of AD presenting with a very fast time course of progression resembling the one of CJD have
been described, named rapidly progressive AD (rpAD). It has been shown that these cases do not
differ to typical AD patients in terms of neuropathological features, thus suggesting that Aβ variants
(i.e., strains) could be implicated in their atypical and faster presentation [122,123]. The correlation
between AD phenotype and the presence of different Aβ conformers within the CNS will be discussed
more in details later in this review.
3.2. Prion-Like Properties of Aβ
After inconclusive attempts of transmission of AD pathology in nonhuman primates [124], one
group injected AD brain homogenates intracerebrally into marmosets (Callithrix jacchus) and, after an
incubation period of approximately 6–7 years, found an increase in senile plaque load with associated
argyrophilic dystrophic neurites and cerebral amyloid angiopathy in the brain in the absence of
neurofibrillary tangles [125]. Subsequently, after the introduction of the APP transgenic mouse model,
several groups performed the injection of Aβ-rich brain extracts from AD patients or aged APP
transgenic mice into APP transgenic hosts [126–136] showing that it was possible to recapitulate
Aβ deposition (i.e., Aβ plaques and cerebral Aβ angiopathy) even using sub-attomolar amounts
of brain-derived Aβ [137]. Furthermore, it was shown that Aβ aggregation in the brain can be
triggered by seeds delivered to the peritoneal cavity [138,139] and that stainless-steel wires coated
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with Aβ-rich brain extract were able to induce plaque formation following implantation in the brain of
APP transgenic mice [140].
In another work, the kinetics of spontaneous and induced Aβ deposition in living mice has
been investigated using bioluminescence imaging (BLI) [141]. The uninoculated biogenic mice Tg
(APP23:Gfap-luc) showed an increase in the BLI signal (i.e., deposition of fluorescent Aβ) in their
brains starting at 416 ± 9 dpi, while mice intracerebrally inoculated with brain homogenates from two
aged Tg mouse models, Tg (APP23) or Tg (CRND8), displayed an increase in the brain BLI signal at 261
± 8 and 238 ± 12 dpi, respectively. The BLI signal remained low in mice inoculated with aged non-Tg
brain homogenate until 333 ± 9 dpi. Interestingly, despite unilateral inoculation, the pathology was
bilateral, suggesting the progressive spread of Aβ deposition throughout the brain. The same group
performed the injection experiments also with the recombinant synthetic Aβ aggregates. In these
experiments, Aβ aggregates were obtained in vitro and then intracerebrally inoculated into young
Tg (APP23:Gfap-luc) mice giving rise to an increase and an anticipation of the emission of the brain
BLI signals [141,142]. Interestingly, pathological investigations showed that synthetic Aβ 40 prions
produced amyloid plaques containing both Aβ 40 and Aβ 42 species in the brains of inoculated mice,
whereas synthetic Aβ 42 stimulated the formation of smaller, more numerous plaques composed
predominantly of Aβ 42 [142]. However, as with PrP, the seeding power of synthetic Aβ was less than
the one displayed by Aβ aggregates obtained from diseased brain, thus suggesting the opportunity
that cofactors present within the CNS could facilitate Aβ spreading [9]. Recently, Purro et al., analyzed
cadaveric pituitary-derived growth hormone (c-hGH) batches used in the past to treat patients that
subsequently developed iCJD associated with relevant Aβ deposition, showing that they contain
substantial levels of Aβ40, Aβ42 and tau proteins. Furthermore, this material was able to seed the
formation of Aβ plaques and cerebral Aβ-amyloid angiopathy in intracerebrally inoculated mice
expressing a mutant, humanized amyloid precursor protein [143]. It is important to note that, although
these studies suggest that Aβ aggregates behave like prions at the molecular level, there is currently
no evidence that AD is infectious in the sense that it is transmissible among humans [144,145].
3.3. AD Heterogeneity: Aβ Strains
Given that the large phenotypical heterogeneity of prion disorders can be explained by the
presence of different strains of PrPSc, after the discovery of prion-like features of Aβ, increasing
interest has been directed towards the study of the structure of Aβ molecules within AD diseased
brains and its potential link with AD clinical diversity. The first evidence that Aβ polymorphism
may correlate with variations in clinical and pathological features of AD derives from the observation
that Aβ40 fibrils with different molecular structures exhibit different levels of toxicity in primary
neuronal cell cultures [146]. In another study, fibrils extracted from AD brains seeded the aggregation
of synthetic Aβ in vitro obtaining different Aβ descendant species, thus providing indirect evidence
for the structural heterogeneity of Aβ among AD brains. The same study also showed the presence
of a pool of Aβ conformers in the same brain with a single dominant species among the others [147].
Other proofs of the existence of intersubject, different Aβ conformers derive from studies on rapidly
progressive AD (rpAD) brains. Using novel biophysical techniques, as conformation-dependent
immunoassay (CDI) and conformational stability assay (CSA), it was shown that even if rpAD cases
do not differ from classical cases on a neuropathological basis, they display the presence of Aβ42
fibrils with specific biochemical features, like the size distributions of aggregates and their resistance
to chemical denaturation [122,123]. Furthermore, Aβ fibrils of an AD diseased brain with a very high
degree of Aβ deposition tested negative when probed with the high-affinity Pittsburgh compound B
(PiB), suggesting the presence of a different Aβ conformer presenting a low density of PiB binding
sites [148]. This was also the case of familial AD patients with the Arctic (Aβ(E22G)) or Osaka
(Aβ(E22∆)) mutations in the Aβ precursor protein (APP) gene, which tested negative for amyloid
PET with the PiB compound, which is commonly used to detect Aβ deposits in sporadic AD (sAD)
cases [22] despite showing a severe cerebral amyloid burden in a postmortem analysis [24,25].
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Recently, three different groups focused their attention on the study of the correlation between AD
diversity and the presence of structural Aβ conformers within the same brain of AD subjects or between
subjects displaying atypical phenotypic features or harboring a disease-causing APP mutation [19–21].
In the first of these studies, luminescent conjugated oligothiophenes (LCOs) were used and biochemical
analyses were carried out to evaluate the variation and structural properties of amyloid in the plaques
of patients with AD from different etiological backgrounds (familial forms, sporadic forms and one
single PiB-negative AD case) providing evidence for the existence of heterogeneous Aβ-amyloid
structures that cluster across different patients with AD. Furthermore, the Aβ-rich brain extracts from
different subtypes of AD transmitted to Tg mice and seeded Aβ deposits correspondingly differentiable
using LCOs which mirrored, even if not completely, those present in the donor brain. The authors
suggest that this uncomplete correspondence of fibril structures between donors and recipients was
probably due to the presence of a mixture of Aβ species in the donor extract which may follow a
Darwinian strain selection [20].
In another study, Condello et al. showed that Aβ deposits from fAD (Aβ(E22G)) and fCAA
(Aβ(E22Q)) patients could be distinguished from sAD patients based on the shape of the emission
spectra of multiple amyloid-staining dyes which are influenced by the conformational Aβ strain. They
also inoculated Tg mice expressing only WT Aβ with synthetic Aβ40 fibrils containing fAD-associated
mutations, showing that mutant Aβ induced the formation of plaques with reduced intensity for
amyloid dyes consistent with the strain features observed in the respective human fAD brain [19].
Thus, mutant Aβ40 prions induce a conformation of WT Aβ similar to that found in fAD deposits,
suggesting that the deposition pattern within specific regions of AD patients is likely defined by
the first stable Aβ prion formed through a kinetically dominant self-propagation process, ultimately
defining diverse AD phenotypes [19].
Recently, another group showed that in both sporadic and inherited forms of AD, amyloid
aggregates differ in the biochemical composition of Aβ species, including aggregation kinetics, the
resistance to degradation by proteases and the seeding ability [21]. As in the other studies, they also
confirmed that brain homogenates from AD patients with different molecular profiles of Aβ are able
to induce distinct patterns of Aβ-amyloidosis when injected into mice [21].
4. Tau
4.1. Tau Protein and Tauopathies
Tau proteins are members of the microtubule-associated proteins (MAP) family. In humans, they
are found mainly in neurons [149], with trace amounts in peripheral tissues [150] and in nonneuronal
cells, especially in pathological conditions [151]. Although people commonly refer to tau as a single
protein, they are actually a small family of six isoforms, originating from the alternative splicing of the
MAPT gene located on chromosome 17q21 [150] in humans. Given this clarification, from now on, we
will refer to tau as a single entity wherever it is not necessary to discriminate. MAPT gene has 16 exons,
but only some of them are constitutively translated [152]. Exons 2, 3 and 10 are alternatively spliced in
the adult brain, giving rise to the different isoforms, that range from 37 to 46 kDa [153]. MAPT exons 2
and 3 encode each for an N-terminal insertion of 29 amino acids, and exon 3 is never present without
exon 2. Exon 10 encodes the second (R2) out of four highly conserved imperfect repeated regions of
31 amino acids, which constitute the microtubule-binding domain of tau proteins, the other being
encoded by exons 9, 11 and 12. Taken together, these splicing variations yield six tau isoforms that
differ for the presence of zero, one or two N-terminal insertions (0N, 1N and 2N) and the presence of
either 3 or 4 imperfect repeats (3R and 4R) in the C-terminal part of the protein.
Tau protein expression is developmentally regulated, with fetal brain expressing only 0N3R tau
(also called “fetal tau”), while in adult CNS all isoforms are present, although at different levels [154].
The ratio between 3R- and 4R-tau isoforms is around 1:1 in healthy brains. Maintaining this equilibrium
is crucial to avoid the onset of pathological conditions, as many tau-related disorders show the
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prevalence of one class of isoforms over the other [155]. Tau protein functions are strictly related to its
structure. Like α-synuclein, tau is a hydrophilic protein which maintains a highly flexible and unfolded
conformation in solution [156]. The N-terminal part has a high content of acidic residues through
which it interacts with cytoskeletal components [157] and cytosolic organelles [158] and determines
the spacing between microtubules, thus affecting the diameter of axons [159]. The central proline-rich
sequence is involved in interactions with receptor proteins [160,161], mediating many important roles
in signal transduction pathways.
The repeated regions R1–R4 located in the C-terminal part of the protein are involved in the
binding of tau to the microtubules network, along with the less-conserved inter-repeat regions.
In particular, they regulate the tau ability to promote the polymerization of tubulin into mature
microtubules, inhibit the rate of depolymerization [162] and are involved in axonal transport [163–165].
Tau proteins undergo a number of posttranslational modifications, including ubiquitination, glycation,
acetylation, nitration and phosphorylation (for a complete overview, see Reference [166]). More than 80
phosphorylation sites have been identified along the amino acidic sequence [152], suggesting that this
modification has deep impacts on tau physiological functions. The addition of phosphate groups on
specific residues of tau is essential to modulate its binding affinity for the microtubules [167]: the higher
phosphate groups content, the lower the ability to interact with tubulin. Tau hyperphosphorylation
on the proline-rich region [168] and the C-terminus [169] induce the self-aggregation of the cytosolic
protein, which forms first oligomeric species and then insoluble fibrils. Several lines of evidence
indicate that abnormal tau phosphorylation might promote neurodegeneration also by compromising
axonal integrity and synaptic functions [170] and by protecting it from degradation by the proteasome
system [171].
Neurodegenerative conditions known as tauopathies have as a common feature the accumulation
of insoluble inclusions called neurofibrillary tangles in the cell bodies of neurons and glia. Interestingly,
the pattern of deposition and the biochemical characteristics of tau aggregates are often disease-specific,
suggesting the existence of different tau strains. Remarkably, tau pathology can either be the
primary cause of disease or can present itself in co-occurrence with the deposition of at least another
amyloidogenic protein, like α-synuclein or huntingtin.
A comparative biochemistry of tau pathological aggregates shows that they differ in both
phosphorylation and content of tau isoforms, which enable a molecular classification of tauopathies.
In fact, according to the biochemical properties of aggregated tau proteins, a sort of “bar code” has
been established to classify tauopathies (Figure 3B) [172]. Class 0 includes rare syndromes in which
there is complete loss of tau protein expression. Class I is the most populated, comprising around 10
diseases characterized by three electrophoretic bands at 60, 64 and 69 kDa and by a fourth, weaker
band at 70/74 kDa. This profile corresponds to the presence of aggregates made of all six isoforms.
The prototypical neurological disorder that characterizes class I is Alzheimer’s disease, but this class
includes nine additional neurological disorders such as hippocampal tauopathy in cerebral aging,
amyotrophic lateral sclerosis parkinsonism-dementia complex of Guam, Parkinsonism with dementia
of Guadeloupe and many others. Class II includes only 4R tauopathies, in which tau amyloids form a
doublet at 64 and 69 kDa. This pathological tau profile is observed in Progressive Supranuclear Palsy
(PSP), Corticobasal Degeneration (CBD), Argyrophylic Grain Disease (AGD) and FTDP-17. Class III
includes a single neurological disorder that is Pick’s disease (PiD). Class III tauopathies show a doublet
at 60 and 64 kDa, corresponding to aggregates of 3R tau. The last class (i.e., IV) includes only specific
forms of myotonic dystrophy characterized by the accumulation of aggregated fetal tau at 60 kDa.
In AD, the intraneuronal spreading of tau pathology goes together with the extracellular
accumulation of Aβ plaques, which the relationship with tau-mediated toxicity is not yet clear. The
main components of AD tangles are paired helical and straight filaments containing both 3R and 4R
isoforms with a high degree of phosphorylation. The one-to-one ratio of 3R and 4R tau in the deposits
is a peculiar characteristic of only some tauopathies, like AD and Frontotemporal Dementia linked to
chromosome 17 (FTLD-17), while the other syndromes all show a dramatic prevalence of one class
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of isoforms [172]. In PSP, AGD and CBD, the aggregates are made exclusively of 4R tau, while Pick’s
Disease is a 3R-tauopathy. The presence of different isoforms reflects distinct electrophoretic profiles
from diseased brains, as well as in filaments assembly. A cryo-EM and immune-EM analysis of both
PHF and SF from multiple cases of sporadic and inherited AD showed that the core structures of
all the filaments are well-conserved and adopt a common fold [173]. Tau fibrils from Pick’s disease
adopt instead a different conformation, which shares a similar pattern with AD but results in a distinct
overall beta packing [174]. These findings establish the existence of molecular conformers of tau
filaments and suggest that additional folds may be found in other tauopathies, such as PSP and CBD,
which share the same isoform composition. Such diversity, mainly at turn residues between conserved
secondary structure motifs as in PiD and AD filaments, might be responsible for the unique phenotypes
of different 4R tauopathies.
4.2. Prion-Like Properties of Tau
As for other proteins mentioned in this review, the tau protein also appears to share some key
features with the prion protein. In 2009, Clavaguera et al. showed that brain extracts from tau
P301S-expressing mice injected into wild-type hosts triggers wild-type tau assembly into filaments
and the spreading of the pathology to the regions surrounding the injection site [175]. This work
highlighted another important feature of aggregated tau, that is, the ability to template the misfolding
of the endogenous protein and its assembly into fibrils. An in vitro study went deeper into this issue,
identifying aggregates composed at least of three protein monomers as the minimal propagation unit
necessary for the internalization and induction of seeding in a HEK293 cell line [176]. Specifically, the
aggregation-competent portion of the tau protein must include the microtubule binding domains, as the
formation of fibrils is strictly dependent on the presence of at least one of the two hexapeptide motifs,
275VQIINK280 and 306VQIVYK311, located respectively at the beginning of the third (R3) and of the
second (R2) repeated regions [177]. A subsequent number of studies conducted both in cell and animal
models further defined the prion-like properties of aggregated tau protein. In these works, tau seeds
were collected either from patients with an array of tauopathies [178] or from symptomatic transgenic
mice [179] or generated by in vitro fibrillization reactions from recombinant material [18,180]. In all
cases, amyloid tau recruited the native protein and triggered its aggregation, although with variable
seeding potency.
The observation that tau aggregates derived from diseased brain homogenates have a 10-fold
higher seeding activity compared to synthetic amyloids and that recombinant monomeric protein
acquires the molecular properties of the in vivo aggregates if seeded with in vivo produced
amyloids [179] suggests that conformational differences deriving from the aggregation process may
account for the variations in seeding capacity. This has been shown also in other works where
distinct conformers of tau were able to faithfully replicate their own morphologies in the newly
formed aggregates, both in vitro [18] and in vivo [178,181]. Furthermore, tau-induced pathology
does not remain limited to the injection site but propagates to the neighboring regions, following
synaptic connections. It is now widely accepted that tau aggregates move transsynaptically and
are taken up by the cells through multiple mechanisms, including micropinocytosis [179], heparan
sulphate proteoglycans [36,182], bulk endocytosis [183] and tunneling nanotubes [184,185]. In the
study mentioned above [175], Clavaguera et al. showed also the spreading of tau pathology from
the transenthorinal cortex of mice to the hippocampus and cerebral cortex, which are anatomically
connected to the injection site. Others confirmed this pattern of propagation [180,186,187], finding
aggregated tau also in distant brain areas like the olfactory and limbic systems [187]. The appearance
of pathological tau species in brain areas around the injection site is often accompanied by the selective
loss of neurons in those regions [188]. Using a model in which tau transgene expression was restricted
specifically to the enthorinal cortex, de Calignon [189] et al. and Liu et al. [190] unequivocally proved
the hypothesis of the transsynaptic spreading of tau aggregates, as they were able to observe tau
pathology in regions not expressing the human transgene but anatomically connected to the enthorinal
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cortex. Furthermore, mice with impairments in exosomal transport and in microglia, which plays
key roles in phagocytosis and exocytosis, show a drastic reduction in tau pathology spreading [191].
Altogether, these data support the idea of tau acting as a prion-like protein; however, the parallelism
with the prion protein does not apply when considering prion infectivity. Indeed, to date, no cases of
transmission of tauopathies between individuals have been reported.
4.3. Tau Strains
The morphology of tau assemblies could be an important determinant in defining the type of
disease that will develop. Indeed, if we consider the three classes of tauopathies (3R, 4R and 3R/4R),
we could immediately notice that the protein material is the same, but it must be assembled in specific
conformations that end up causing distinct pathologies. Structural insights into filaments made of
recombinant tau isoforms proved that at least three types of fibrils exist, each one with individual
characteristics: 3R aggregates, 4R aggregates and mixed aggregates composed of both types of isoforms
that co-assemble into heterogeneous amyloids [192]. Thanks to their conformational plasticity, tau
isoforms assume multiple conformations when grown on homogeneous or heterogeneous fibrils.
However, an asymmetric seeding barrier exists between the 3R and 4R isoforms, probably dictated by
the secondary structures that each type of isoforms assumes. While 3R tau can recruit all isoforms, 4R
tau is not able to interact with 3R tau, and when they are both present, each one forms its own single
fibers, which then combine into the mixed aggregates found in AD [193,194]. A high-resolution of
AD-containing filaments were recently obtained from material purified from AD brains, confirming
that the number of R regions deeply impacts fibrils formation and morphology [195].
Mutations in the primary sequence of tau are responsible for the vast majority of tau pathologies,
and currently, more than 32 mutations have been identified in over 100 families [196]. Half of these
mutations impact at the protein level, altering tau interaction with microtubules and promoting its
assembly into abnormal filaments. The different biochemical properties of the mutated amino acid
might also affect the hydrophobic and long-range interactions that allow fibrils formation, therefore
affecting the final conformations of the assemblies. Indeed, using circular dichroism and spectroscopy
techniques, Frost et al., showed that aggregates composed of wild-type or mutated (P301L/V337M) tau
have different secondary structures and morphology [197]. In particular, the latter displays a curved
morphology and lacks the typical helical appearance of the wild-type fibrils. A similar effect on the
overall structure of the aggregates has been observed also for other amino acidic substitutions located
in the central and C-terminal part of the sequence [198], as well as a different sensitivity to proteolytic
cleavage [199]. Strikingly, each specific conformer could template the misfolding of the monomeric
protein carrying the same mutation but was less efficient in seeding all the others, thus pointing
towards a strain-like behavior of the aggregates. However, in some cases the copresence of two or
more different tau proteins triggers cross-seeding events and gives rise to brand new morphomers,
which, in turn, propagate their structure in subsequent passages. While P301L was not able to misfold
wild-type tau after one single round of seeding reaction [199], when the double mutant P301L/V337M
was used, a new conformer, termed WT*, was produced after four rounds of seeding reaction of the
wild-type monomer [197].
It is noteworthy that although the protein composition of WT* fibrils was the same of the wild-type
aggregates, their tertiary structure was clearly distinct, with a greater content in random coil elements
and a reduced number of alpha helices. Indeed, electron microscopy analysis revealed a stronger
similarity with mutated fibrils, which had been used as a template only in the first cycle of the seeding
reaction. This peculiar conformer can be classified as a proper strain, since it is able to maintain its
structural characteristics over time. The ability to form stable strains is not exclusively dependent
on the presence of mutations, although the molecular basis of the phenomenon remains largely
unknown. The exposure of cells expressing only the microtubule-binding domains of tau fused to YFP
(HEK293-RD-YFP) to synthetic fibrils led to the obtainment of 20 distinct clones, among which the most
representative (clone 9 and clone 10) were selected and further characterized [18]. Differences were
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clearly visible in the inclusion morphology, aggregate size and subcellular localization and extended
also to biochemical properties, like protease sensitivity, seeding capacity and toxicity. Moreover, all the
specific characteristics are maintained when the aggregates are transferred to naïve cells, and also to
transgenic P301S mice where they initiate unique pathological phenotypes in distinct cell types. The
authors propose that clone 9 and clone 10 might represent the final products of specific cell responses
to different aggregates morphologies, mirrored by their cell compartmentalization. The pattern of
spreading followed by clone 9 in mice gave further prove of the ability of tau aggregates to move
through anatomic connections.
Guo et al. [200] identified striking differences in the morphological structure of AD-seeded
fibrils compared to in vitro ones, which affected their seeding potency and deposition pattern. This
phenomenon is not limited to AD; indeed, the inoculation of mice transgenic for human wild-type tau
(ALZ17) with brain extracts from patients with different tauopathies recapitulated the major features
of each disease [178]. After 6 months from the injection, all injected mice developed inclusions in the
injection site, and in some cases (brain extracts of AGD, PSP and CBD), the morphologies of the newly
formed aggregates were specific and consistent with the human counterparts in the brains of patients.
It, thus, appears that several tau conformers made of the same tau isoform (4R tau in this case) exist in
different tauopathies. Aggregates from Pick’s Disease were less efficient in templating the misfolding
and aggregation processes, probably due to the lower tendency of 3R tau to assemble into amyloid
structures. However, using the ultrasensitive technique, Real Time Quaking Induced Conversion
reaction (RT-QuIC), Saijo et al. [201] were able to detect the seeding activity in PiD brain extracts
even at very high dilutions. The same cell model that allowed the identification and characterization
of the two strains termed clone 9 and 10 was then applied to further investigate the contribution
of strains to the spectrum of human tauopathies [18]. Twenty-nine samples from patients with a
variety of tauopathies served as seeds to template the aggregation of tau RD-YFP, which formed
several inclusions that were subsequently characterized and scored according to their morphology.
The analysis revealed distinct strain compositions across the pathologies, with AD showing the highest
homogeneity probably correlated to the existence of a predominant strain. On the contrary, other
diseases had strong interpatient variations, with at least two individual strains identified (PSP and
AGD). Notably, the homogeneous behavior of AD-induced cellular aggregates mirrors the in vivo
pathology, which is characteristically more uniform.
Although these data represent a substantial achievement in the overall understanding of the
strain phenomenon, the authors themselves point out that other different conformers could be present
that did not succeed in seeding tau RD-YFP and, thus, could not be detected. Moreover, some strains
from the PiD and AGD samples were not stable in cell culture, impeding their further characterization.
To test whether these putative strains were able to reproduce their array of pathological phenotypes
also in vivo, mice expressing human 1N4R tau P301S were inoculated with cell lysates from each line
used to amplify the strains [181]. Regarding the rates of propagation throughout the brain, in vivo
data correlated with that observed in vitro, with the strains with higher seeding activity spreading
faster, except for strain 10 which remained confined in the contralateral region of the hippocampus. All
injected mice showed signs of tau pathology, albeit with great variations only in part consistent with the
in vitro behavior. While the amount of AT8-positive aggregates paralleled with the seeding activity of
the strain, the morphologies of the aggregates were unique for the specific strain, ranging from typical
grain pathology (DS18) to fibers “wisps” resembling neuropil threads (DS7). Interestingly, conformers
with the same proteolysis pattern also shared similar seeding activity and toxicity and induced similar
phenotypes in cultured cells, suggesting that these properties are conformation-specific. Furthermore,
they do not depend on the monomeric protein used as a substrate but are totally dependent on the
pathological aggregate used as seed.
When brain extracts from patients with 4R and mixed tauopathies (AD, PSP and CBD) were
inoculated in non-transgenic mice [202], a similar situation to P301S mice was observed, with specific
inclusions forming in different subcellular localization according to the type of biological sample.
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AD-tau induced a thread-like pathology mainly in axons and triggered the aggregation of both 3R and
4R endogenous tau, while CBD seeds induced frequent perykarial pathology made predominantly
of 4R tau. Among PSP strains, one in particular that came from the frontal cortex of the patient was
found to be uniquely aggressive, with a very fast rate of spreading throughout the brain. Although
showing variable seeding potency, all the three groups of strains maintained cell specificity for neurons
or glia as in the corresponding disease such that only PSP and CBD samples induced astroglial and
oligodendroglial pathology with coiled bodies that closely resemble their human counterparts. The
presence of glial inclusions is particularly relevant, since it was believed that only neurons expressed a
significant amount of tau protein. Moreover, glial amyloids significantly contributed to the spreading
of the disease, either by transmission between glial cells or through the axons of neurons from the
white matter. The use of non-transgenic mice as a model allowed the limitations caused by the spatial
distribution of tau transgene overexpression that could influence the spreading of the aggregates to
be overcome. Furthermore, the PSP and CBD strains analyzed are the first that showed consistent
glial pathology.
5. Alpha-Synuclein
5.1. Alpha-Synuclein and Alpha-Synucleinopathies
Alpha-synuclein is a 140-amino-acid protein expressed mainly at the synaptic terminals of neurons
in the central, peripheral and enteric nervous systems. Alpha-synuclein plays key roles in regulating the
cell-to-cell communication and neurotransmitter release [203]. The protein amino acidic sequence can
be divided in three segments according to their biochemical properties: the N-terminal lipid-binding
domain, the amyloidogenic central portion or Non Aβ Component (NAC) and the C-terminal acidic
tail. Understanding α-synuclein behavior in solution and its tendency to aggregate is crucial. The first
domain spans amino acids 1–87 and is enriched in positively charged residues, organized in seven
repeats of 11 aa, each containing the hexapeptidic motif KTKEGV. The amphipatic nature of these
repeats induces the formation of helical structures that mediate the interaction with lipid bilayers [204].
The central core of α-synuclein (61–95) partially overlaps with the previous domain and is responsible
for amyloid formation, as it forms cross-beta structures independently of the presence of the other
two domains [205]. At the C-terminus, the last 43 amino acids are arranged in a random coil structure
characterized by a high net negative charge and a subsequent low hydrophobicity. Intriguingly,
convincing evidence proves that this domain inhibits α-synuclein aggregation by shielding the
fragment of the NAC region through a long-range interaction with both the hydrophobic cluster
of the NAC itself and the positive charges of the N-terminus [206]. Indeed, the C-terminal truncation of
α-synuclein is enhanced in familial cases of PD and is associated with the initiation of its aggregation
in vivo [207].
In addition, the C-terminal domain is homologous with the α-crystalline domain of small heath
shock proteins, which are known to bind partially unfolded proteins and to prevent their accumulation
into larger aggregates [208]. This similarity, together with the stability of α-synuclein in extreme
conditions (high temperature and high concentration of electrolytes) points towards an involvement in
the protection against thermal and oxidative stress. The native disordered conformation of α-synuclein
is thermodynamically metastable [209], which means that its self-aggregation into various amyloid
structures in vivo is a favorable process, tightly regulated by the proteome homeostasis and chaperone
machineries. As aging progresses, the gradual impairment of the homeostatic system impairs the
surveillance over the formation of aggregated species and leads to a dramatic increase in the incidence
of synucleinopathies [210]. Despite being all defined by the abnormal aggregation of the same
protein, α-synucleinopathies show a variety of symptoms and clinical manifestations [211]. Among
them, the most studied are idiopathic PD, Dementia with Lewy Bodies (DLB) and Multiple System
Atrophy (MSA). While they are all characterized by a progressive decline in motor and cognitive
functions, the pattern of the lesions is specific for each disease. PD is clinically associated with
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motor symptoms, including rest tremor, rigidity, bradykinesia and stooping posture. Non-motor
manifestations encompass neurobehavioral disorders (depression and anxiety), cognitive impairment
(dementia) and autonomic dysfunction (e.g., orthostasis and hyperhidrosis). In PD, aggregated
α-synuclein accumulates in neuronal perikarya (Lewy bodies) and neuronal processes (Lewy neurites).
The disease process is multifocal and involves central nervous system neurons and also the enteric
and autonomous nervous systems [212,213]. DLB is clinically dominated by a cognitive decline which
usually precedes or begins within a year with parkinsonism. Usually dementia is associated with
recurrent visual hallucinations, fluctuating cognition, rapid eye movement sleep behavior disorder
and severe sensitivity to antipsychotic medications. In DLB α-synuclein aggregates present the
same characteristics of those in PD, usually presenting with a major involvement of cortical brain
regions [214]. MSA is defined by the presence of filamentous α-synuclein inclusions (Papp–Lantos
bodies) within the cytoplasm of glial cells, together with tau- and ubiquitin-positive inclusions [215].
The symptoms include autonomic failure, urogenital dysfunctions, cerebellar ataxia and parkinsonism.
5.2. Alpha-Synuclein Prion-Like Properties
The first evidence for a prion-like mechanism of the α-synuclein spreading was provided by a
postmortem observation of healthy neurons grafted in the brain of PD patients, which developed
aggregates of α-synuclein similar to those of the host neurons [216,217]. Following these observations,
Desplats and collaborators showed that α-synuclein is transmitted via endocytosis from neuronal cells
overexpressing the protein to neighboring neurons, forming Lewy Bodies (LB)-like inclusions [218].
Additionally, in vivo studies showed that α-synuclein was transmitted from the affected neurons to
engrafted neuronal precursor cells in a Tg mice model of PD-like pathology, leading to inclusion
body formation [218]. Furthermore, MSA-derived α-synuclein aggregates inoculated in Tg mice
expressing mutant α-synuclein showed the ability to recruit the endogenously expressed mutant
protein and to template the formation of LBs-like structures [219]. In the attempt to confirm that
the ability to induce pathology was dependent on the protein itself and was not related to unknown
host factors present in the aggregates extracted from diseased brains, the efficiency of synthetic
α-synuclein assemblies to induce pathology both in vitro and in vivo has been tested, demonstrating
that in vitro-formed aggregates, both oligomers and fibrils, may be taken up and may propagate
among cells in a prion-like manner, inducing LB-like pathology [33,218,220–225]. Indeed, human
recombinant α-synuclein aggregates were able to induce the aggregation of endogenous α-synuclein
in non-transfected human neuroblastoma SH-SY5Y cells [226].
Furthermore, Luk and collaborators showed that the addition of in vitro-preformed α-synuclein
fibrils into a cell culture medium induces intracellular α-synuclein aggregation in different cell lines
overexpressing the protein [222]. When tested in vivo, recombinant α-synuclein aggregates efficiently
replicated and spread from the site of injection to anatomically connected regions in transgenic [221]
and, importantly, wild-type animals [220]. Another group confirmed these results [223], showing
that α-synuclein pathology caused the progressive loss of dopamine neurons in the substantia nigra
pars compacta and caused impairment in motor coordination in mice injected with both pathological
DLB brain-derived α-synuclein aggregates (i.e., the sarkosyl-insoluble fraction) and recombinant
α-synuclein assemblies obtained in vitro. Alpha-synuclein pathology was absent when mice were
injected with the soluble recombinant protein [223]. Subsequently, other groups showed the “infectious”
activity of LB extracts from PD diseased brains in mice and also in monkeys [227]. Although all these
studies clearly showed the prion properties of α-synuclein assemblies [228], so far there is no evidence
of pathologic α-synuclein aggregate transmission between individuals leading to the use of the
prion-like definition to make a distinction between this protein and actively infectious prions [229,230].
5.3. Alpha-Synuclein Strains
As already mentioned, numerous studies unequivocally proved that recombinant α-synuclein
aggregated in vitro can spread from cell to cell both in cultured cells [218,226,231] and in murine
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brains [220,221], resulting in neuronal dysfunction. Moreover, once injected, synthetic amyloids
recruit the endogenous protein and template its misfolding into LB/Lewy Neurite-like structures,
which closely resemble those found in patients [220,221,225]. Given the ability of α-synuclein to
populate multiple conformational states in solution, changes in the environment, even minimal,
can shift the equilibrium towards a specific intermediate that would grow into a distinct fibrillary
assembly. Recombinant α-synuclein readily polymerizes in vitro in the presence of physiological
concentrations of salts to form cylindrical structures, while under lower salt concentrations, the
formed amyloids flatten and twist, resembling a sort of ribbon [232]. The different architecture of the
morphomers reflects in their functional properties, as fibrils are resistant to proteinase K and exhibit
a higher toxicity in cultured cells. Upon incubation with neuroblastoma cell lines, both aggregates
transmit their intrinsic structures and features to endogenous α-synuclein, imprinting a unique
and heritable pattern of puncta [232]. Although the NAC region alone is sufficient for α-synuclein
fibrillization [205], the presence of the N-terminal domain and, to a lesser extent, of the C-terminus
affects the final conformation of the aggregates [26]. In a work by Guo et al., full-length α-synuclein
originates specific morphological aggregates, called “strain A” [26], which cannot be replicated by
N-terminal-truncated forms of the protein (58–140). Self-seeding fibrillization studies showed that
strain A conformation could be transmitted to the partially truncated 32–140 form of α-synuclein but
not to 58–140 α-synuclein, suggesting that the segment 32–57 is essential for the strain propagation,
while 1–31 is not an integral part of the core of the fibrils.
As already mentioned above, the C-terminus tends to impede α-synuclein aggregation by masking
the NAC region through its negative charges. Indeed, when subjected to in vitro fibrillization,
truncated 1–120 α-synuclein gives rise to a number of different conformers that cannot be stably
propagated via repetitive self-seeding. This effect is in part abolished by the addition after residue 120
of a myc tag, which the negative charges of mimics in part the presence of the acidic tail and allows
the formation of a different conformer, termed “strain B” [26]. Therefore, the C-terminal part seems to
counteract the action of the N-terminus by impeding structural diversity. In the specific case of strain
A and B, the two amyloids show a peculiar behavior in seeding both α-synuclein and tau pathology in
in vivo models, with strain B being far more competent in seeding tau aggregation in transgenic mice
than strain A [26]. The different inductions of tau inclusions were analyzed with a panel of antibodies
that recognize pathological tau conformations. Strain-specific conformations can be imprinted also
by posttranslational modifications, such as the phosphorylation of serine 129, which is a hallmark of
pathological lesions in diseased brains [233]. pSer129α-synuclein fibers show a higher toxicity and
distinct morphology compared to wild-type fibers and could propagate their intrinsic properties to the
endogenous protein in cell cultures [234]. Interestingly, the phosphorylation of other residues did not
lead to any change in fibrils morphology, implying that residue 129 must be involved in some sort of
transient interaction that inhibits aggregation.
As mentioned above, the inoculation of both transgenic and non-transgenic mice with synthetic
α-synuclein assemblies produces a pathology that is characterized by the presence of Lewy body/Lewy
neurite structures in defined brain regions. The pattern of lesions and the pathological phenotypes
observed in injected rodents are dependent on the intrinsic nature of the aggregates, thus corroborating
the hypothesis of the existence of α-synuclein strains in vivo. Indeed, α-synuclein fibrils and ribbons,
after mice administration, imposed a different burden on the affected brain, with fibrils resulting
in progressive motor impairment and cell death while ribbons caused a distinct histopathological
phenotype characterized by Parkinson’s disease and multiple system atrophy traits [27]. These
appealing results provide a tentative explanation to the variability in symptoms and affected
brain areas, which could be dictated by the structural and biochemical properties of the amyloids
involved. The observation that only α-synuclein ribbons could propagate into oligodendrocyte cells,
a feature that is typical of MSA, suggested for the first time a possible connection between distinct
α-synucleinopathies and strains [232]. The inoculation of transgenic mice expressing A53T mutant
α-synuclein with brain homogenates containing MSA-derived aggregates led to the instauration of
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a pathological condition which could be transmitted to other groups of mice faithfully propagating
its own characteristics [28,219]. The accumulation of α-synuclein was primarily neuronal, probably a
consequence of the weak expression of the transgene in oligodendrocyte cells; however, the peculiarities
shown by both MSA seeds and spontaneous A53T seeds in Tg83+/+ mice and their differences in
terms of distribution and incubation time are sufficient to classify them as separate strains. This notion
is reinforced by the fact that PD seeds, on the contrary, failed to induce PD pathology in the same
transgenic model, while in C57BL/6 mice and in macaques initiated a Lewy body-like pathology that
spread throughout the CNS [227]. A similar behavior occurs for DLB-derived aggregates, which elicited
α-synuclein hyperphosphorylation and aggregation into Lewy body-like structures in wild-type
mice [223].
While PD and DLB aggregates triggered the aggregation and the pathological phosphorylation
of the endogenous protein, MSA seeds could not propagate in the absence of A53T α-synuclein. The
different identity of MSA and PD α-synuclein strains reflects in the unique clinical presentation of
these disorders and in the specific aggregate deposition in the CNS: oligodendrocyte cells throughout
the neuraxis in MSA, neuronal perikarya and axons of substantia nigra and striatum in PD. Not only the
identity of misfolded seeds but also the intracellular environment prompts significantly the generation
of α-synuclein strains. As shown by Peng et al., LB aggregates injected in a mice line engineered to
express α-synuclein only in oligodendrocytes are able to propagate between cells, and as they spread,
they lose their biochemical characteristics and acquire glial cytoplasmic inclusion (GCI)-like features,
such as a higher seeding potency. Lysates of the same cells retain the ability to convert misfolded
α-synuclein, in this case, synthetic preformed fibrils, into GCI-like structures. On the contrary, GCI
seeds maintain their identity after multiple passages in neurons, supporting the hypothesis that the
generation of their features depends on the presence of factors specific to oligodendrocytes and absent
in neuronal cells [235].
6. TDP-43
6.1. TDP-43 in ALS and FTLD
One of the main characteristics of sporadic ALS (sALS) cases is the presence of motor neuronal
inclusions in the CNS of affected subjects, which stain positively for ubiquitin [4]. In 2006, two different
groups discovered that the protein TDP-43 was the major component of these aggregates in the spinal
cord and brains of ALS subjects and of tau-negative and ubiquitin-positive inclusions in Frontotemporal
lobar degeneration (FTLD) brains [236,237]. In these deposits, TDP-43 is hyperphosphorylated,
ubiquitinated and abnormally cleaved to generate C-terminal fragments (CTFs). Collectively, these
NDDs are named TDP-43 proteinopathies [238]. TDP-43 is encoded by the TARDBP gene on
chromosome 1, which encodes for a 414-amino-acid protein ubiquitously expressed in all tissues
and is well-conserved in invertebrates and mammals [4]. TDP-43 contains a nuclear localization signal
(NLS) and two RNA recognition motifs (RRMs) followed by a glycine-rich domain. This protein
is a multifunctional DNA/RNA-binding protein involved in many cellular processes, including
micro-RNA processing [239], apoptosis [240], RNA transcription, alternative splicing and mRNA
stability regulation [241,242], thus suggesting its essential role in many molecular and cellular processes,
confirmed by the embryo lethality of its mouse knockout model [243–245]. The N-terminal portion
of TDP-43, including two RNA recognition motifs (RRMs), is thought to have a folded conformation,
whereas the C-terminal portion is unstructured and is considered to be aggregation prone [246].
After the identification of TDP-43 as the major protein component of intraneuronal aggregates
in ALS and FTLD, several pathological mutations in the TARDBP gene have been identified in
subjects affected by familial and sporadic forms of ALS and in a restricted number of subjects
with FTLD [240,247–249], thus confirming a direct link between this protein and pathology. It is
now well-known that ALS and FTLD can clinically overlap with ALS patients displaying cognitive
impairment or signs of FTD in approximately 50% and 15% of the cases, respectively [250]. This
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strict connection has also been confirmed by a neuropathological analysis which identified TDP-43
pathology in the majority of sALS cases (around 95%) and in 60% of FTLD cases [4]. FTLD-TDP can be
classified according to the shape and distribution of the pathological TDP-43 lesions in the CNS. This
classification was harmonized in 2001 [251] and recently revised with the addition of a new subtype
with specific clinical and histopathological features [252]. Interestingly, every histopathological subtype
(from A to E) presents a distinct WB banding pattern of the hyperphosphorylated protein extracted as
the sarkosyl-insoluble fraction of brain homogenates and is also related to specific clinical features and
genetic background (Figure 3C) [252].
Type A is defined by large numbers of short dystrophic neurites and crescent or oval shaped
neuronal cytoplasmic inclusions (NCIs). Type A is associated with behavioral variant FTD (bvFTD) or
nonfluent/agrammatic primary progressive aphasia (naPPA) and mutations in the Progranulin gene
(GRN). Type B is associated with mild levels of NCIs in all the cortical layers and only a few short
dystrophic neurites. Type B has been correlated to patients with ALS and FTD and presents a link with
the C9ORF72 expansion. Type C is characterized by numerous long dystrophic neurites, mainly in
cortical layer 2 and a few NCIs. Type C has been associated with the semantic dementia variant of FTD.
Type C cases are typically sporadic FTD having no association with any known disease-causing genetic
mutations. Type D consists of numerous short dystrophic neurites, lentiform neuronal intranuclear
inclusions and a few NCIs throughout all layers of the cortex. Type D pathology is directly associated
with patients with inclusion body myopathy with early onset Paget’s disease and FTD (IBMPFTD)
caused by valosin-containing protein (VCP) mutations. Type E is defined by the predominance of
ubiquitin-negative granulofilamentous neuronal inclusions (GFNI’s) over compact neuronal inclusions,
the presence of abundant, very fine grey matter grains together with the presence of oligodendroglial
inclusions. Type E is mainly associated with bvFTD, characterized by a rapidly progressive clinical
course and seems to have no association with any known genetic mutation [252].
6.2. The Prion-Like Properties of TDP-43
Several studies have shown the intrinsic propensity of TDP-43 to aggregate [253–255]. The ability
of TDP-43 aggregates to act as seeds in vitro and, very recently, in vivo has been demonstrated [256].
The first evidence of TDP-43 prion-like properties comes from the work of Johnson et al. in 2009 [255],
which showed an increase in the turbidity of a solution containing the full-length TDP-43 recombinant
protein (recTDP-43FL) at room temperature and constant agitation. The same experiment was repeated
using the N- and C-terminal fragments of the protein, and the increase in turbidity of the solution (i.e.,
aggregation) was observed only in the presence of the C-terminal region of TDP-43, confirming the
crucial role of this region of the protein for its aggregation. The connection between the C-terminal part
of the protein and pathology has also been confirmed by a genetic analysis of the TARDBP gene, since
the majority of the identified pathogenic mutations clusters in the region of the gene which encodes for
the C-terminus of TDP-43 [240,247–249]. When probed with ThT or Congo red, the final products of this
reaction did not show a specific binding with these dyes, suggesting the absence of β-sheet structures in
recTDP-43 aggregates [255]. Although initial pathological studies suggested that TDP-43 pathological
aggregates displayed nonamyloid structures [257,258], a subsequent analysis showed the presence of
amyloid structures in the spinal cord of a subset of ALS patients [259] and that the use of a different
pretreatment of CNS tissues form ALS and FTLD-TDP patients allowed an increased detection of
amyloid positive TDP-43 inclusions [260]. Another study by Furukawa et al. showed that recTDP-43FL
aggregates obtained in vitro were moderately able to bind ThT, thus demonstrating the presence in
their conformation of β-sheet structures [253]. When analyzed in electron microscopy, these aggregates
presented a fibrillary morphology, confirming what was observed with the ThT binding. They also
showed the seeding capacity of recombinant wild-type and mutant-insoluble TDP-43 aggregates
into HEK293 cells under TDP-43 (with a C-terminal His-tag; TDP-43-HA) overexpressing conditions.
These aggregates were able to seed the fibrillization of endogenous TDP-43-HA and contained the
pathological C-terminal fragments (CTFs) within the aggregates, even if, in this case, there was no
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evidence of hyperphosphorylation of the aggregated intracellular protein as it occurs in ALS and
FTLD-TDP diseased brains [253].
A crucial study for the demonstration of the seeding ability of TDP-43 aggregates was performed
in 2013 by Nonaka and colleagues. This group transfected human TDP-43 aggregates collected
from ALS and FTLD-TDP diseased brains into SH-SY5Y cells with and without overexpressing the
full-length human wild-type TDP-43. Only cells which were overexpressing the protein and that were
treated with the brain extract containing the pathological TDP-43 aggregates showed the presence of
bands of the hyperphosphorylated protein in a WB analysis in the sarkosyl-insoluble fraction of their
lysates. They also showed that pathological aggregates were toxic to cells, probably via an impairment
of the cellular proteasome system and that the seeding reaction was time-dependent (i.e., bands
appeared and increased in their intensity after the third day postinfection) and “self-templating” [261].
By self-templating the authors mean that the banding pattern observed at the WB analysis of the
sarkosyl-insoluble fraction of the affected cells mostly corresponded to one of the pathological proteins
extracted from the brain used as a seed. The seeding activity of pathological diseased brain extracts
was recently confirmed by another group in a murine motor neuron-like cell line (NSC-34) under
TDP-43 overexpressing conditions [262]. Finally, Porta et al. showed that intracerebral injections of
biologically active pathogenic FTLD-TDP seeds into transgenic mice expressing cytoplasmic human
TDP-43 and also non-transgenic mice led to the induction of de novo TDP-43 pathology. Moreover, this
group showed that TDP-43 pathology progressively spreads throughout the brain in a time-dependent
manner, supposedly via the neuroanatomic connectome [256].
6.3. TDP-43 Strains
As for TSEs, ALS also displays different phenotypes with the opportunity to have a predominant
involvement of the upper or lower motor neurons, the clinical onset possibly involving spinal or
bulbar muscles and, as already mentioned, the association with cognitive impairment in a continuum
with Frontotemporal dementia [263]. Frontotemporal dementia, for its part, can also present with the
impairment of different cognitive abilities with predominant behavioral or language impairment [252].
Furthermore, according to neuropathological examination, FTLD-TDP, as mentioned earlier, can be
classified in different histopathological subtypes according to the shape and distribution of TDP-43
positive lesions [252]. All these observations led to the speculation that different conformations
or “strains” of misfolded TDP-43 might be responsible for the wide variety of different clinical
ALS/FTLD phenotypes related to a specific strain-related distribution in preferential CNS areas.
The hypothesis of the existence of different TDP-43 aggregated species in the CNS of FTLD-TDP
subjects is corroborated by the fact that there is a specific western blot banding pattern associated
with each histopathological subtype (Figure 3C), thus suggesting different biochemical properties and
conformations of the pathological aggregated TDP-43. Another proof in this direction was provided by
the already mentioned seeding experiment performed by Nonaka et al. using SH-SY5Y cells in which
it was shown that aggregates extracted from a specific brain with a predominant histopathological
subtype were able to template the same biochemical properties (i.e., the same specific western blot
banding pattern) on the endogenous wild-type TDP-43 protein [261]. Shimonaka et al., used TDP-43
aggregates obtained by the in vitro fibrillization of different C-terminal TDP-43 peptides to transduce
cells expressing wild-type or mutant TDP-43 protein and showed that the sarkosyl-insoluble fraction
of these cell lysates contained different phosphorylated C-terminal fragments of TDP-43 and different
trypsin-resistant bands. These results suggest that the templated aggregation of TDP-43 by seeding
with different peptides induced various types of TDP-43 pathologies, i.e., the peptides appear to act
like prion strains [264]. Finally, it was recently shown that pathological TDP-43 brain extracts were
able to spread in the CNS after injection in Tg and, less efficiently, in non-Tg mice. Also in this case, it
was noted that not all subtypes of TDP-43 species had the same infectious ability. Moreover, this group
performed an in vitro assessment of the brain extract seeding activity, observing that FTLD-TDP-GRN
lysates had the highest activity followed by FTLD-TDP-C9ORFf72 and sporadic FTLD-TDP cases [256].
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However, more extensive biochemical and biophysical studies are needed to show the presence of
distinct pathogenic TDP-43 strains in FTLD-TDP and ALS CNS, possibly related to the presence
of different TDP-43 conformers (i.e., strains) with a specific tropism for selected brain areas and
characterized by a different seeding ability, resulting, ultimately, in the extreme clinical heterogeneity
observed in FTLD-TDP and ALS patients.
7. Conclusions
Although NDDs show marked differences in terms of clinical and neuropathological features,
increasing evidence suggests that they share a common pathogenic characteristic: the presence of
deposits of misfolded proteins with altered physicochemical properties in the CNS [1,2]. In recent
years, several reports suggest that all misfolded protein accumulated in NDDs diseased brains are
able to template their misfolding onto their respective native counterparts in a process which closely
resembles the prion replication cycle [10], called prion-like mechanism [2]. The prion-like features
displayed by misfolded proteins involved in neurodegeneration led to relevant implications. Indeed,
it seems that, as prions, each protein is able to acquire not just one misfolded conformation but several
and that every possible different conformer (i.e., a strain) can result from a process of selection or
adaptation (Figure 2). From a single molecule or from a pool of conformers present in the affected
tissue, the process could lead to the efficient replication and accumulation of a dominant one, able to
prevail among the others. In this context, it should be noted that the presence of multiple pathological
misfolded protein conformers in a single patient or among different affected subjects poses to the
scientific community several unanswered issues:
(i) if prion and prion-like proteins are subjected to evolution, should we also expect an
increase/evolution of misfolding-related disorders? In a recent work, it has been shown that
vCJD infectious agent(s) contained in soluble or insoluble fractions of human vCJD blood
donors was/were able to replicate in macaques generating typical and nonconventional vCJD
phenotypes, the latter characterized by the presence of PK-sensitive PrPSc deposition and atypical
clinical features mainly involving the spinal cord [93]. These results clearly suggest that prions
show the ability to modify not only their structure but also their clinical manifestations after the
infectious passage between human donors and nonhuman primates and that this “evolution” is
dependent on the infectious source utilized.
(ii) How accurate are the diagnostic tools that we are currently using to discriminate between
different NDDs entities? In fact, if diagnostic molecules are not able to bind all the possible
misfolded conformers, as it was shown for the PiB ligand for Aβ [24,25,148], it is not possible to
reliably classify the disease. Such a lack of reliable diagnostic tests could reduce our accuracy
in studying the neurodegenerative process and also the sensibility and specificity in selecting
possible candidates for clinical studies and pharmacological trials.
(iii) The same concept applies for therapeutic molecules. As indicated by Rasmussen et al., the
discovery of multiple Aβ conformers associated with different AD clinical entities suggests the
need for the development of drugs with multiple targets or for the use of a pool of polyclonal
antibodies directed against the wider range of amyloid pathological structures [20].
In light of all these considerations, it is of utmost importance to clearly understand the molecular
basis leading to strain formation and propagation to develop targeted diagnostic and therapeutic
strategies. Reconsidering proteinopathies as “conformational disorders” could allow the development
of strain- and, thus, patient-oriented strategies in order to face the high heterogeneity displayed by
neurodegenerative disorders.
Author Contributions: C.S. and E.D.C. wrote and prepared the original draft of this paper. P.M. reviewed the
original draft. G.L. reviewed the original draft and supervised the preparation of the manuscript.
Funding: The APC was funded by the JPND-REfrAME project.
Viruses 2019, 11, 261 25 of 37
Acknowledgments: G.L. acknowledges support from the JPND-REfrAME project. The authors would like to
acknowledge Giulia Salzano for her technical support in the figures preparation.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Kovacs, G.G. Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards
Precision Medicine. Int. J. Mol. Sci. 2016, 17, 189. [CrossRef] [PubMed]
2. Maniecka, Z.; Polymenidou, M. From nucleation to widespread propagation: A prion-like concept for ALS.
Virus Res. 2015, 207, 94–105. [CrossRef] [PubMed]
3. Moore, R.A.; Taubner, L.M.; Priola, S.A. Prion protein misfolding and disease. Curr. Opin. Struct. Biol. 2009,
19, 14–22. [CrossRef] [PubMed]
4. Smethurst, P.; Sidle, K.C.; Hardy, J. Review: Prion-like mechanisms of transactive response DNA binding
protein of 43 kDa (TDP-43) in amyotrophic lateral sclerosis (ALS). Neuropathol. Appl. Neurobiol. 2015, 41,
578–597. [CrossRef] [PubMed]
5. Holmes, B.B.; Diamond, M.I. Amyotrophic lateral sclerosis and organ donation: Is there risk of disease
transmission? Ann. Neurol. 2012, 72, 832–836. [CrossRef] [PubMed]
6. Jucker, M.; Walker, L.C. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative
disorders. Ann. Neurol. 2011, 70, 532–540. [CrossRef] [PubMed]
7. Aguzzi, A. Cell biology: Beyond the prion principle. Nature 2009, 459, 924–925. [CrossRef]
8. Prusiner, S.B. Biology and genetics of prions causing neurodegeneration. Annu. Rev. Genet. 2013, 47, 601–623.
[CrossRef]
9. Walker, L.C.; Jucker, M. Neurodegenerative diseases: Expanding the prion concept. Annu. Rev. Neurosci.
2015, 38, 87–103. [CrossRef]
10. Prusiner, S.B. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216, 136–144. [CrossRef]
11. Prusiner, S.B. Prions. Proc. Natl. Acad. Sci. USA 1998, 95, 13363–13383. [CrossRef]
12. Bistaffa, E.; Moda, F.; Virgilio, T.; Campagnani, I.; De Luca, C.M.G.; Rossi, M.; Salzano, G.; Giaccone, G.;
Tagliavini, F.; Legname, G. Synthetic Prion Selection and Adaptation. Mol. Neurobiol. 2018. [CrossRef]
13. Morales, R.; Abid, K.; Soto, C. The prion strain phenomenon: Molecular basis and unprecedented features.
Biochim. Biophys. Acta 2007, 1772, 681–691. [CrossRef]
14. Bartz, J.C.; Bessen, R.A.; McKenzie, D.; Marsh, R.F.; Aiken, J.M. Adaptation and selection of prion protein
strain conformations following interspecies transmission of transmissible mink encephalopathy. J. Virol.
2000, 74, 5542–5547. [CrossRef]
15. Colby, D.W.; Giles, K.; Legname, G.; Wille, H.; Baskakov, I.V.; DeArmond, S.J.; Prusiner, S.B. Design and
construction of diverse mammalian prion strains. Proc. Natl. Acad. Sci. USA 2009, 106, 20417–20422.
[CrossRef]
16. Legname, G.; Baskakov, I.V.; Nguyen, H.O.; Riesner, D.; Cohen, F.E.; DeArmond, S.J.; Prusiner, S.B. Synthetic
mammalian prions. Science 2004, 305, 673–676. [CrossRef]
17. Peelaerts, W.; Bousset, L.; Baekelandt, V.; Melki, R. α-Synuclein strains and seeding in Parkinson’s disease,
incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: Similarities and
differences. Cell Tissue Res. 2018, 373, 195–212. [CrossRef]
18. Sanders, D.W.; Kaufman, S.K.; DeVos, S.L.; Sharma, A.M.; Mirbaha, H.; Li, A.; Barker, S.J.; Foley, A.C.;
Thorpe, J.R.; Serpell, L.C.; et al. Distinct tau prion strains propagate in cells and mice and define different
tauopathies. Neuron 2014, 82, 1271–1288. [CrossRef]
19. Condello, C.; Lemmin, T.; Stohr, J.; Nick, M.; Wu, Y.; Maxwell, A.M.; Watts, J.C.; Caro, C.D.; Oehler, A.;
Keene, C.D.; et al. Structural heterogeneity and intersubject variability of Abeta in familial and sporadic
Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 2018, 115, E782–E791. [CrossRef]
20. Rasmussen, J.; Mahler, J.; Beschorner, N.; Kaeser, S.A.; Hasler, L.M.; Baumann, F.; Nystrom, S.; Portelius, E.;
Blennow, K.; Lashley, T.; et al. Amyloid polymorphisms constitute distinct clouds of conformational variants
in different etiological subtypes of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 2017, 114, 13018–13023.
[CrossRef]
21. Di Fede, G.; Catania, M.; Maderna, E.; Ghidoni, R.; Benussi, L.; Tonoli, E.; Giaccone, G.; Moda, F.; Paterlini, A.;
Campagnani, I.; et al. Molecular subtypes of Alzheimer’s disease. Sci. Rep. 2018, 8, 3269. [CrossRef]
Viruses 2019, 11, 261 26 of 37
22. Jack, C.R., Jr.; Lowe, V.J.; Senjem, M.L.; Weigand, S.D.; Kemp, B.J.; Shiung, M.M.; Knopman, D.S.; Boeve, B.F.;
Klunk, W.E.; Mathis, C.A.; et al. 11C PiB and structural MRI provide complementary information in
imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain J. Neurol. 2008, 131, 665–680.
[CrossRef]
23. Kalimo, H.; Lalowski, M.; Bogdanovic, N.; Philipson, O.; Bird, T.D.; Nochlin, D.; Schellenberg, G.D.;
Brundin, R.; Olofsson, T.; Soliymani, R.; et al. The Arctic AbetaPP mutation leads to Alzheimer’s disease
pathology with highly variable topographic deposition of differentially truncated Abeta. Acta Neuropathol.
Commun. 2013, 1, 60. [CrossRef]
24. Scholl, M.; Wall, A.; Thordardottir, S.; Ferreira, D.; Bogdanovic, N.; Langstrom, B.; Almkvist, O.; Graff, C.;
Nordberg, A. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation
carriers. Neurology 2012, 79, 229–236. [CrossRef]
25. Tomiyama, T.; Nagata, T.; Shimada, H.; Teraoka, R.; Fukushima, A.; Kanemitsu, H.; Takuma, H.; Kuwano, R.;
Imagawa, M.; Ataka, S.; et al. A new amyloid beta variant favoring oligomerization in Alzheimer’s-type
dementia. Ann. Neurol. 2008, 63, 377–387. [CrossRef]
26. Guo, J.L.; Covell, D.J.; Daniels, J.P.; Iba, M.; Stieber, A.; Zhang, B.; Riddle, D.M.; Kwong, L.K.; Xu, Y.;
Trojanowski, J.Q.; et al. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell
2013, 154, 103–117. [CrossRef]
27. Peelaerts, W.; Bousset, L.; Van der Perren, A.; Moskalyuk, A.; Pulizzi, R.; Giugliano, M.; Van den Haute, C.;
Melki, R.; Baekelandt, V. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic
administration. Nature 2015, 522, 340–344. [CrossRef]
28. Prusiner, S.B.; Woerman, A.L.; Mordes, D.A.; Watts, J.C.; Rampersaud, R.; Berry, D.B.; Patel, S.; Oehler, A.;
Lowe, J.K.; Kravitz, S.N.; et al. Evidence for alpha-synuclein prions causing multiple system atrophy in
humans with parkinsonism. Proc. Natl. Acad. Sci. USA 2015, 112, E5308–E5317. [CrossRef]
29. Holmqvist, S.; Chutna, O.; Bousset, L.; Aldrin-Kirk, P.; Li, W.; Bjorklund, T.; Wang, Z.Y.; Roybon, L.; Melki, R.;
Li, J.Y. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta
Neuropathol. 2014, 128, 805–820. [CrossRef]
30. Rey, N.L.; Petit, G.H.; Bousset, L.; Melki, R.; Brundin, P. Transfer of human alpha-synuclein from the olfactory
bulb to interconnected brain regions in mice. Acta Neuropathol. 2013, 126, 555–573. [CrossRef]
31. Sacino, A.N.; Brooks, M.; Thomas, M.A.; McKinney, A.B.; Lee, S.; Regenhardt, R.W.; McGarvey, N.H.;
Ayers, J.I.; Notterpek, L.; Borchelt, D.R.; et al. Intramuscular injection of alpha-synuclein induces CNS
alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc. Natl. Acad. Sci. USA
2014, 111, 10732–10737. [CrossRef]
32. Mao, X.; Ou, M.T.; Karuppagounder, S.S.; Kam, T.I.; Yin, X.; Xiong, Y.; Ge, P.; Umanah, G.E.; Brahmachari, S.;
Shin, J.H.; et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene
3. Science 2016, 353, aah3374. [CrossRef]
33. Aulic, S.; Masperone, L.; Narkiewicz, J.; Isopi, E.; Bistaffa, E.; Ambrosetti, E.; Pastore, B.; De Cecco, E.;
Scaini, D.; Zago, P.; et al. alpha-Synuclein Amyloids Hijack Prion Protein to Gain Cell Entry, Facilitate
Cell-to-Cell Spreading and Block Prion Replication. Sci. Rep. 2017, 7, 10050. [CrossRef]
34. Victoria, G.S.; Zurzolo, C. The spread of prion-like proteins by lysosomes and tunneling nanotubes:
Implications for neurodegenerative diseases. J. Cell Biol. 2017, 216, 2633–2644. [CrossRef]
35. Malm, T.; Loppi, S.; Kanninen, K.M. Exosomes in Alzheimer’s disease. Neurochem. Int. 2016, 97, 193–199.
[CrossRef]
36. Holmes, B.B.; DeVos, S.L.; Kfoury, N.; Li, M.; Jacks, R.; Yanamandra, K.; Ouidja, M.O.; Brodsky, F.M.;
Marasa, J.; Bagchi, D.P.; et al. Heparan sulfate proteoglycans mediate internalization and propagation of
specific proteopathic seeds. Proc. Natl. Acad. Sci. USA 2013, 110, E3138–E3147. [CrossRef]
37. Aguzzi, A.; Miele, G. Recent advances in prion biology. Curr. Opin. Neurol. 2004, 17, 337–342. [CrossRef]
38. Del Rio, J.A.; Ferrer, I.; Gavin, R. Role of cellular prion protein in interneuronal amyloid transmission. Prog.
Neurobiol. 2018, 165–167, 87–102. [CrossRef]
39. Del Rio, J.A.; Gavin, R. Functions of the cellular prion protein, the end of Moore’s law, and Ockham’s razor
theory. Prion 2016, 10, 25–40. [CrossRef]
40. Linden, R.; Martins, V.R.; Prado, M.A.; Cammarota, M.; Izquierdo, I.; Brentani, R.R. Physiology of the prion
protein. Physiol. Rev. 2008, 88, 673–728. [CrossRef]
Viruses 2019, 11, 261 27 of 37
41. Prusiner, S.B.; Scott, M.R.; DeArmond, S.J.; Cohen, F.E. Prion protein biology. Cell 1998, 93, 337–348.
[CrossRef]
42. Stahl, N.; Borchelt, D.R.; Hsiao, K.; Prusiner, S.B. Scrapie prion protein contains a phosphatidylinositol
glycolipid. Cell 1987, 51, 229–240. [CrossRef]
43. Ford, M.J.; Burton, L.J.; Morris, R.J.; Hall, S.M. Selective expression of prion protein in peripheral tissues of
the adult mouse. Neuroscience 2002, 113, 177–192. [CrossRef]
44. Miele, G.; Alejo Blanco, A.R.; Baybutt, H.; Horvat, S.; Manson, J.; Clinton, M. Embryonic activation and
developmental expression of the murine prion protein gene. Gene Expr. 2003, 11, 1–12. [CrossRef]
45. Tichopad, A.; Pfaffl, M.W.; Didier, A. Tissue-specific expression pattern of bovine prion gene: Quantification
using real-time RT-PCR. Mol. Cell Probes 2003, 17, 5–10. [CrossRef]
46. Legname, G.; Moda, F. The Prion Concept and Synthetic Prions. Prog. Mol. Biol. Transl. Sci. 2017, 150,
147–156.
47. Head, M.W.; Ironside, J.W. Review: Creutzfeldt-Jakob disease: Prion protein type, disease phenotype and
agent strain. Neuropathol. Appl. Neurobiol. 2012, 38, 296–310. [CrossRef]
48. Imran, M.; Mahmood, S. An overview of animal prion diseases. Virol. J. 2011, 8, 493. [CrossRef]
49. Pattison, I.H.; Millson, G.C. Scrapie produced experimentally in goats with special reference to the clinical
syndrome. J. Comp. Pathol. 1961, 71, 101–109. [CrossRef]
50. Tenover, F.C.; Arbeit, R.D.; Goering, R.V.; Mickelsen, P.A.; Murray, B.E.; Persing, D.H.; Swaminathan, B.
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: Criteria
for bacterial strain typing. J. Clin. Microbiol. 1995, 33, 2233–2239.
51. Caughey, B.; Raymond, G.J.; Bessen, R.A. Strain-dependent differences in beta-sheet conformations of
abnormal prion protein. J. Biol. Chem. 1998, 273, 32230–32235. [CrossRef]
52. Safar, J.; Wille, H.; Itri, V.; Groth, D.; Serban, H.; Torchia, M.; Cohen, F.E.; Prusiner, S.B. Eight prion strains
have PrP(Sc) molecules with different conformations. Nat. Med. 1998, 4, 1157–1165. [CrossRef]
53. Wadsworth, J.D.; Hill, A.F.; Joiner, S.; Jackson, G.S.; Clarke, A.R.; Collinge, J. Strain-specific prion-protein
conformation determined by metal ions. Nat. Cell Biol. 1999, 1, 55–59. [CrossRef]
54. Aucouturier, P.; Kascsak, R.J.; Frangione, B.; Wisniewski, T. Biochemical and conformational variability of
human prion strains in sporadic Creutzfeldt-Jakob disease. Neurosci. Lett. 1999, 274, 33–36. [CrossRef]
55. Bellon, A.; Seyfert-Brandt, W.; Lang, W.; Baron, H.; Groner, A.; Vey, M. Improved conformation-dependent
immunoassay: Suitability for human prion detection with enhanced sensitivity. J. Gen. Virol. 2003, 84,
1921–1925. [CrossRef]
56. Jones, E.M.; Surewicz, W.K. Fibril conformation as the basis of species- and strain-dependent seeding
specificity of mammalian prion amyloids. Cell 2005, 121, 63–72. [CrossRef]
57. Bessen, R.A.; Marsh, R.F. Identification of two biologically distinct strains of transmissible mink
encephalopathy in hamsters. J. Gen. Virol. 1992, 73 Pt 2, 329–334. [CrossRef]
58. Bruce, M.E. Scrapie strain variation and mutation. Br. Med. Bull. 1993, 49, 822–838. [CrossRef]
59. Fraser, H. Diversity in the neuropathology of scrapie-like diseases in animals. Br. Med. Bull. 1993, 49,
792–809. [CrossRef]
60. Bessen, R.A.; Marsh, R.F. Biochemical and physical properties of the prion protein from two strains of the
transmissible mink encephalopathy agent. J. Virol. 1992, 66, 2096–2101.
61. Collinge, J.; Sidle, K.C.; Meads, J.; Ironside, J.; Hill, A.F. Molecular analysis of prion strain variation and the
aetiology of ‘new variant’ CJD. Nature 1996, 383, 685–690. [CrossRef]
62. Parchi, P.; Castellani, R.; Capellari, S.; Ghetti, B.; Young, K.; Chen, S.G.; Farlow, M.; Dickson, D.W.; Sima, A.A.;
Trojanowski, J.Q.; et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann.
Neurol. 1996, 39, 767–778. [CrossRef]
63. Khalili-Shirazi, A.; Summers, L.; Linehan, J.; Mallinson, G.; Anstee, D.; Hawke, S.; Jackson, G.S.; Collinge, J.
PrP glycoforms are associated in a strain-specific ratio in native PrPSc. J. Gen. Virol. 2005, 86, 2635–2644.
[CrossRef]
64. Bruce, M.E.; McBride, P.A.; Farquhar, C.F. Precise targeting of the pathology of the sialoglycoprotein, PrP,
and vacuolar degeneration in mouse scrapie. Neurosci. Lett. 1989, 102, 1–6. [CrossRef]
65. Bruce, M.E.; Boyle, A.; Cousens, S.; McConnell, I.; Foster, J.; Goldmann, W.; Fraser, H. Strain characterization
of natural sheep scrapie and comparison with BSE. J. Gen. Virol. 2002, 83, 695–704. [CrossRef]
Viruses 2019, 11, 261 28 of 37
66. Lasmezas, C.I.; Deslys, J.P.; Demaimay, R.; Adjou, K.T.; Hauw, J.J.; Dormont, D. Strain specific and common
pathogenic events in murine models of scrapie and bovine spongiform encephalopathy. J. Gen. Virol. 1996,
77 Pt 7, 1601–1609. [CrossRef]
67. Fraser, H.; Dickinson, A.G. Scrapie in mice. Agent-strain differences in the distribution and intensity of grey
matter vacuolation. J. Comp. Pathol. 1973, 83, 29–40. [CrossRef]
68. Brown, P.; Gibbs, C.J., Jr.; Rodgers-Johnson, P.; Asher, D.M.; Sulima, M.P.; Bacote, A.; Goldfarb, L.G.;
Gajdusek, D.C. Human spongiform encephalopathy: The National Institutes of Health series of 300 cases of
experimentally transmitted disease. Ann. Neurol. 1994, 35, 513–529. [CrossRef]
69. Parchi, P.; Giese, A.; Capellari, S.; Brown, P.; Schulz-Schaeffer, W.; Windl, O.; Zerr, I.; Budka, H.; Kopp, N.;
Piccardo, P.; et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic
analysis of 300 subjects. Ann. Neurol. 1999, 46, 224–233. [CrossRef]
70. Meissner, B.; Kallenberg, K.; Sanchez-Juan, P.; Collie, D.; Summers, D.M.; Almonti, S.; Collins, S.J.; Smith, P.;
Cras, P.; Jansen, G.H.; et al. MRI lesion profiles in sporadic Creutzfeldt-Jakob disease. Neurology 2009, 72,
1994–2001. [CrossRef]
71. Zerr, I.; Pocchiari, M.; Collins, S.; Brandel, J.P.; de Pedro Cuesta, J.; Knight, R.S.; Bernheimer, H.; Cardone, F.;
Delasnerie-Laupretre, N.; Cuadrado Corrales, N.; et al. Analysis of EEG and CSF 14-3-3 proteins as aids to
the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000, 55, 811–815. [CrossRef]
72. Mead, S.; Gandhi, S.; Beck, J.; Caine, D.; Gallujipali, D.; Carswell, C.; Hyare, H.; Joiner, S.; Ayling, H.;
Lashley, T.; et al. A novel prion disease associated with diarrhea and autonomic neuropathy. N. Engl. J. Med.
2013, 369, 1904–1914. [CrossRef]
73. Goldfarb, L.G.; Petersen, R.B.; Tabaton, M.; Brown, P.; LeBlanc, A.C.; Montagna, P.; Cortelli, P.; Julien, J.;
Vital, C.; Pendelbury, W.W.; et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: Disease
phenotype determined by a DNA polymorphism. Science 1992, 258, 806–808. [CrossRef]
74. Monari, L.; Chen, S.G.; Brown, P.; Parchi, P.; Petersen, R.B.; Mikol, J.; Gray, F.; Cortelli, P.; Montagna, P.;
Ghetti, B.; et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: Different prion proteins
determined by a DNA polymorphism. Proc. Natl. Acad. Sci. USA 1994, 91, 2839–2842. [CrossRef]
75. Lasmezas, C.I.; Deslys, J.P.; Robain, O.; Jaegly, A.; Beringue, V.; Peyrin, J.M.; Fournier, J.G.; Hauw, J.J.;
Rossier, J.; Dormont, D. Transmission of the BSE agent to mice in the absence of detectable abnormal prion
protein. Science 1997, 275, 402–405. [CrossRef]
76. Manuelidis, E.E.; Gorgacz, E.J.; Manuelidis, L. Transmission of Creutzfeldt-Jakob disease with scrapie-like
syndromes to mice. Nature 1978, 271, 778–779. [CrossRef]
77. Muramoto, T.; Kitamoto, T.; Tateishi, J.; Goto, I. Successful transmission of Creutzfeldt-Jakob disease from
human to mouse verified by prion protein accumulation in mouse brains. Brain Res. 1992, 599, 309–316.
[CrossRef]
78. Tateishi, J.; Sato, Y.; Nagara, H.; Boellaard, J.W. Experimental transmission of human subacute
spongiform encephalopathy to small rodents. IV. Positive transmission from a typical case of
Gerstmann-Straussler-Scheinker’s disease. Acta Neuropathol. 1984, 64, 85–88. [CrossRef]
79. Bruce, M.; Chree, A.; McConnell, I.; Foster, J.; Pearson, G.; Fraser, H. Transmission of bovine spongiform
encephalopathy and scrapie to mice: Strain variation and the species barrier. Philos. Trans. R. Soc. Lond. B
Biol. Sci. 1994, 343, 405–411.
80. Fraser, H.; Bruce, M.E.; Chree, A.; McConnell, I.; Wells, G.A. Transmission of bovine spongiform
encephalopathy and scrapie to mice. J. Gen. Virol. 1992, 73 Pt 8, 1891–1897. [CrossRef]
81. Tateishi, J.; Ohta, M.; Koga, M.; Sato, Y.; Kuroiwa, Y. Transmission of chronic spongiform encephalopathy
with kuru plaques from humans to small rodents. Ann. Neurol. 1979, 5, 581–584. [CrossRef]
82. Moore, R.A.; Vorberg, I.; Priola, S.A. Species barriers in prion diseases—Brief review. In Infectious Diseases
from Nature: Mechanisms of Viral Emergence and Persistence; Springer: Vienna, Austria, 2005; pp. 187–202.
83. Peretz, D.; Williamson, R.A.; Legname, G.; Matsunaga, Y.; Vergara, J.; Burton, D.R.; DeArmond, S.J.;
Prusiner, S.B.; Scott, M.R. A change in the conformation of prions accompanies the emergence of a new prion
strain. Neuron 2002, 34, 921–932. [CrossRef]
84. Chianini, F.; Fernandez-Borges, N.; Vidal, E.; Gibbard, L.; Pintado, B.; de Castro, J.; Priola, S.A.; Hamilton, S.;
Eaton, S.L.; Finlayson, J.; et al. Rabbits are not resistant to prion infection. Proc. Natl. Acad. Sci. USA 2012,
109, 5080–5085. [CrossRef]
Viruses 2019, 11, 261 29 of 37
85. Bruce, M.E.; Will, R.G.; Ironside, J.W.; McConnell, I.; Drummond, D.; Suttie, A.; McCardle, L.; Chree, A.;
Hope, J.; Birkett, C.; et al. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent.
Nature 1997, 389, 498–501. [CrossRef]
86. Hill, A.F.; Desbruslais, M.; Joiner, S.; Sidle, K.C.; Gowland, I.; Collinge, J.; Doey, L.J.; Lantos, P. The same
prion strain causes vCJD and BSE. Nature 1997, 389, 448–450. [CrossRef]
87. Ritchie, D.L.; Boyle, A.; McConnell, I.; Head, M.W.; Ironside, J.W.; Bruce, M.E. Transmissions of variant
Creutzfeldt-Jakob disease from brain and lymphoreticular tissue show uniform and conserved bovine
spongiform encephalopathy-related phenotypic properties on primary and secondary passage in wild-type
mice. J. Gen. Virol. 2009, 90, 3075–3082. [CrossRef]
88. Head, M.W.; Bunn, T.J.; Bishop, M.T.; McLoughlin, V.; Lowrie, S.; McKimmie, C.S.; Williams, M.C.;
McCardle, L.; MacKenzie, J.; Knight, R.; et al. Prion protein heterogeneity in sporadic but not variant
Creutzfeldt-Jakob disease: UK cases 1991–2002. Ann. Neurol. 2004, 55, 851–859. [CrossRef]
89. Zeidler, M.; Johnstone, E.C.; Bamber, R.W.; Dickens, C.M.; Fisher, C.J.; Francis, A.F.; Goldbeck, R.; Higgo, R.;
Johnson-Sabine, E.C.; Lodge, G.J.; et al. New variant Creutzfeldt-Jakob disease: Psychiatric features. Lancet
1997, 350, 908–910. [CrossRef]
90. Mok, T.; Jaunmuktane, Z.; Joiner, S.; Campbell, T.; Morgan, C.; Wakerley, B.; Golestani, F.; Rudge, P.; Mead, S.;
Jager, H.R.; et al. Variant Creutzfeldt-Jakob Disease in a Patient with Heterozygosity at PRNP Codon 129. N.
Engl. J. Med. 2017, 376, 292–294. [CrossRef]
91. Bishop, M.T.; Diack, A.B.; Ritchie, D.L.; Ironside, J.W.; Will, R.G.; Manson, J.C. Prion infectivity in the spleen
of a PRNP heterozygous individual with subclinical variant Creutzfeldt-Jakob disease. Brain J. Neurol. 2013,
136, 1139–1145. [CrossRef]
92. Peden, A.; McCardle, L.; Head, M.W.; Love, S.; Ward, H.J.; Cousens, S.N.; Keeling, D.M.; Millar, C.M.;
Hill, F.G.; Ironside, J.W. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult
patient with haemophilia. Haemophilia 2010, 16, 296–304. [CrossRef]
93. Comoy, E.E.; Mikol, J.; Jaffre, N.; Lebon, V.; Levavasseur, E.; Streichenberger, N.; Sumian, C.;
Perret-Liaudet, A.; Eloit, M.; Andreoletti, O.; et al. Experimental transfusion of variant CJD-infected
blood reveals previously uncharacterised prion disorder in mice and macaque. Nat. Commun. 2017, 8, 1268.
[CrossRef]
94. Bessen, R.A.; Marsh, R.F. Distinct PrP properties suggest the molecular basis of strain variation in
transmissible mink encephalopathy. J. Virol. 1994, 68, 7859–7868.
95. Li, J.; Browning, S.; Mahal, S.P.; Oelschlegel, A.M.; Weissmann, C. Darwinian evolution of prions in cell
culture. Science 2010, 327, 869–872. [CrossRef]
96. Berry, D.B.; Lu, D.; Geva, M.; Watts, J.C.; Bhardwaj, S.; Oehler, A.; Renslo, A.R.; DeArmond, S.J.; Prusiner, S.B.;
Giles, K. Drug resistance confounding prion therapeutics. Proc. Natl. Acad. Sci. USA 2013, 110, E4160–E4169.
[CrossRef]
97. Baskakov, I.V.; Aagaard, C.; Mehlhorn, I.; Wille, H.; Groth, D.; Baldwin, M.A.; Prusiner, S.B.; Cohen, F.E.
Self-assembly of recombinant prion protein of 106 residues. Biochemistry 2000, 39, 2792–2804. [CrossRef]
98. Baskakov, I.V.; Legname, G.; Baldwin, M.A.; Prusiner, S.B.; Cohen, F.E. Pathway complexity of prion protein
assembly into amyloid. J. Biol. Chem. 2002, 277, 21140–21148. [CrossRef]
99. Baskakov, I.V.; Legname, G.; Prusiner, S.B.; Cohen, F.E. Folding of prion protein to its native alpha-helical
conformation is under kinetic control. J. Biol. Chem. 2001, 276, 19687–19690. [CrossRef]
100. Hill, A.F.; Antoniou, M.; Collinge, J. Protease-resistant prion protein produced in vitro lacks detectable
infectivity. J. Gen. Virol. 1999, 80 Pt 1, 11–14. [CrossRef]
101. Hsiao, K.K.; Groth, D.; Scott, M.; Yang, S.L.; Serban, H.; Rapp, D.; Foster, D.; Torchia, M.; Dearmond, S.J.;
Prusiner, S.B. Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant
prion protein. Proc. Natl. Acad. Sci. USA 1994, 91, 9126–9130. [CrossRef]
102. Kaneko, K.; Ball, H.L.; Wille, H.; Zhang, H.; Groth, D.; Torchia, M.; Tremblay, P.; Safar, J.; Prusiner, S.B.;
DeArmond, S.J.; et al. A synthetic peptide initiates Gerstmann-Straussler-Scheinker (GSS) disease in
transgenic mice. J. Mol. Biol. 2000, 295, 997–1007. [CrossRef]
103. Tremblay, P.; Ball, H.L.; Kaneko, K.; Groth, D.; Hegde, R.S.; Cohen, F.E.; DeArmond, S.J.; Prusiner, S.B.;
Safar, J.G. Mutant PrPSc conformers induced by a synthetic peptide and several prion strains. J. Virol. 2004,
78, 2088–2099. [CrossRef]
Viruses 2019, 11, 261 30 of 37
104. Peretz, D.; Scott, M.R.; Groth, D.; Williamson, R.A.; Burton, D.R.; Cohen, F.E.; Prusiner, S.B. Strain-specified
relative conformational stability of the scrapie prion protein. Protein Sci. 2001, 10, 854–863. [CrossRef]
105. Kim, C.; Xiao, X.; Chen, S.; Haldiman, T.; Smirnovas, V.; Kofskey, D.; Warren, M.; Surewicz, K.; Maurer, N.R.;
Kong, Q.; et al. Artificial strain of human prions created in vitro. Nat. Commun. 2018, 9, 2166. [CrossRef]
106. Legname, G.; Nguyen, H.O.; Baskakov, I.V.; Cohen, F.E.; Dearmond, S.J.; Prusiner, S.B. Strain-specified
characteristics of mouse synthetic prions. Proc. Natl. Acad. Sci. USA 2005, 102, 2168–2173. [CrossRef]
107. Legname, G.; Nguyen, H.O.; Peretz, D.; Cohen, F.E.; DeArmond, S.J.; Prusiner, S.B. Continuum of prion
protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc. Natl. Acad. Sci. USA
2006, 103, 19105–19110. [CrossRef]
108. Ghaemmaghami, S.; Watts, J.C.; Nguyen, H.O.; Hayashi, S.; DeArmond, S.J.; Prusiner, S.B. Conformational
transformation and selection of synthetic prion strains. J. Mol. Biol. 2011, 413, 527–542. [CrossRef]
109. Saborio, G.P.; Permanne, B.; Soto, C. Sensitive detection of pathological prion protein by cyclic amplification
of protein misfolding. Nature 2001, 411, 810–813. [CrossRef]
110. Zhang, Z.; Zhang, Y.; Wang, F.; Wang, X.; Xu, Y.; Yang, H.; Yu, G.; Yuan, C.; Ma, J. De novo generation
of infectious prions with bacterially expressed recombinant prion protein. FASEB J. 2013, 27, 4768–4775.
[CrossRef]
111. Barria, M.A.; Telling, G.C.; Gambetti, P.; Mastrianni, J.A.; Soto, C. Generation of a new form of human PrP(Sc)
in vitro by interspecies transmission from cervid prions. J. Biol. Chem. 2011, 286, 7490–7495. [CrossRef]
112. Castilla, J.; Gonzalez-Romero, D.; Saa, P.; Morales, R.; De Castro, J.; Soto, C. Crossing the species barrier by
PrP(Sc) replication in vitro generates unique infectious prions. Cell 2008, 134, 757–768. [CrossRef]
113. Gonzalez-Montalban, N.; Lee, Y.J.; Makarava, N.; Savtchenko, R.; Baskakov, I.V. Changes in prion replication
environment cause prion strain mutation. FASEB J. 2013, 27, 3702–3710. [CrossRef]
114. Moda, F.; Le, T.N.; Aulic, S.; Bistaffa, E.; Campagnani, I.; Virgilio, T.; Indaco, A.; Palamara, L.; Andreoletti, O.;
Tagliavini, F.; et al. Synthetic prions with novel strain-specified properties. PLoS Pathog. 2015, 11, e1005354.
[CrossRef]
115. Goedert, M.; Spillantini, M.G. A century of Alzheimer’s disease. Science 2006, 314, 777–781. [CrossRef]
116. O’Brien, R.J.; Wong, P.C. Amyloid precursor protein processing and Alzheimer’s disease. Annu. Rev. Neurosci.
2011, 34, 185–204. [CrossRef]
117. Bergmans, B.A.; De Strooper, B. gamma-secretases: From cell biology to therapeutic strategies. Lancet Neurol.
2010, 9, 215–226. [CrossRef]
118. Shen, J.; Kelleher, R.J., 3rd. The presenilin hypothesis of Alzheimer’s disease: Evidence for a loss-of-function
pathogenic mechanism. Proc. Natl. Acad. Sci. USA 2007, 104, 403–409. [CrossRef]
119. Hof, P.R.; Bouras, C.; Perl, D.P.; Sparks, D.L.; Mehta, N.; Morrison, J.H. Age-related distribution of
neuropathologic changes in the cerebral cortex of patients with Down’s syndrome. Quantitative regional
analysis and comparison with Alzheimer’s disease. Arch. Neurol. 1995, 52, 379–391. [CrossRef]
120. Karantzoulis, S.; Galvin, J.E. Distinguishing Alzheimer’s disease from other major forms of dementia. Expert
Rev. Neurother. 2011, 11, 1579–1591. [CrossRef]
121. Lam, B.; Masellis, M.; Freedman, M.; Stuss, D.T.; Black, S.E. Clinical, imaging, and pathological heterogeneity
of the Alzheimer’s disease syndrome. Alzheimers Res. 2013, 5, 1. [CrossRef]
122. Cohen, M.L.; Kim, C.; Haldiman, T.; ElHag, M.; Mehndiratta, P.; Pichet, T.; Lissemore, F.; Shea, M.; Cohen, Y.;
Chen, W.; et al. Rapidly progressive Alzheimer’s disease features distinct structures of amyloid-beta. Brain J.
Neurol. 2015, 138, 1009–1022. [CrossRef]
123. Cohen, M.; Appleby, B.; Safar, J.G. Distinct prion-like strains of amyloid beta implicated in phenotypic
diversity of Alzheimer’s disease. Prion 2016, 10, 9–17. [CrossRef]
124. Goudsmit, J.; Morrow, C.H.; Asher, D.M.; Yanagihara, R.T.; Masters, C.L.; Gibbs, C.J., Jr.; Gajdusek, D.C.
Evidence for and against the transmissibility of Alzheimer disease. Neurology 1980, 30, 945–950. [CrossRef]
125. Baker, H.F.; Ridley, R.M.; Duchen, L.W.; Crow, T.J.; Bruton, C.J. Evidence for the experimental transmission
of cerebral beta-amyloidosis to primates. Int. J. Exp. Pathol. 1993, 74, 441–454.
126. Duran-Aniotz, C.; Morales, R.; Moreno-Gonzalez, I.; Hu, P.P.; Fedynyshyn, J.; Soto, C. Aggregate-depleted
brain fails to induce Abeta deposition in a mouse model of Alzheimer’s disease. PLoS ONE 2014, 9, e89014.
[CrossRef]
Viruses 2019, 11, 261 31 of 37
127. Duran-Aniotz, C.; Morales, R.; Moreno-Gonzalez, I.; Hu, P.P.; Soto, C. Brains from non-Alzheimer’s
individuals containing amyloid deposits accelerate Abeta deposition in vivo. Acta Neuropathol. Commun.
2013, 1, 76. [CrossRef]
128. Hamaguchi, T.; Eisele, Y.S.; Varvel, N.H.; Lamb, B.T.; Walker, L.C.; Jucker, M. The presence of Abeta seeds,
and not age per se, is critical to the initiation of Abeta deposition in the brain. Acta Neuropathol. 2012, 123,
31–37. [CrossRef]
129. Heilbronner, G.; Eisele, Y.S.; Langer, F.; Kaeser, S.A.; Novotny, R.; Nagarathinam, A.; Aslund, A.;
Hammarstrom, P.; Nilsson, K.P.; Jucker, M. Seeded strain-like transmission of beta-amyloid morphotypes in
APP transgenic mice. EMBO Rep. 2013, 14, 1017–1022. [CrossRef]
130. Kane, M.D.; Lipinski, W.J.; Callahan, M.J.; Bian, F.; Durham, R.A.; Schwarz, R.D.; Roher, A.E.; Walker, L.C.
Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid
precursor protein-transgenic mice. J. Neurosci. 2000, 20, 3606–3611. [CrossRef]
131. Langer, F.; Eisele, Y.S.; Fritschi, S.K.; Staufenbiel, M.; Walker, L.C.; Jucker, M. Soluble Abeta seeds are potent
inducers of cerebral beta-amyloid deposition. J. Neurosci. 2011, 31, 14488–14495. [CrossRef]
132. Meyer-Luehmann, M.; Coomaraswamy, J.; Bolmont, T.; Kaeser, S.; Schaefer, C.; Kilger, E.;
Neuenschwander, A.; Abramowski, D.; Frey, P.; Jaton, A.L.; et al. Exogenous induction of cerebral
beta-amyloidogenesis is governed by agent and host. Science 2006, 313, 1781–1784. [CrossRef]
133. Morales, R.; Duran-Aniotz, C.; Castilla, J.; Estrada, L.D.; Soto, C. De novo induction of amyloid-beta
deposition in vivo. Mol. Psychiatry 2012, 17, 1347–1353. [CrossRef]
134. Rosen, R.F.; Fritz, J.J.; Dooyema, J.; Cintron, A.F.; Hamaguchi, T.; Lah, J.J.; LeVine, H., 3rd; Jucker, M.;
Walker, L.C. Exogenous seeding of cerebral beta-amyloid deposition in betaAPP-transgenic rats. J. Neurochem.
2012, 120, 660–666. [CrossRef]
135. Walker, L.C.; Callahan, M.J.; Bian, F.; Durham, R.A.; Roher, A.E.; Lipinski, W.J. Exogenous induction of
cerebral beta-amyloidosis in betaAPP-transgenic mice. Peptides 2002, 23, 1241–1247. [CrossRef]
136. Ye, L.; Hamaguchi, T.; Fritschi, S.K.; Eisele, Y.S.; Obermuller, U.; Jucker, M.; Walker, L.C. Progression of
Seed-Induced Abeta Deposition within the Limbic Connectome. Brain Pathol. 2015, 25, 743–752. [CrossRef]
137. Fritschi, S.K.; Langer, F.; Kaeser, S.A.; Maia, L.F.; Portelius, E.; Pinotsi, D.; Kaminski, C.F.; Winkler, D.T.;
Maetzler, W.; Keyvani, K.; et al. Highly potent soluble amyloid-beta seeds in human Alzheimer brain but
not cerebrospinal fluid. Brain J. Neurol. 2014, 137, 2909–2915. [CrossRef]
138. Eisele, Y.S.; Obermuller, U.; Heilbronner, G.; Baumann, F.; Kaeser, S.A.; Wolburg, H.; Walker, L.C.;
Staufenbiel, M.; Heikenwalder, M.; Jucker, M. Peripherally applied Abeta-containing inoculates induce
cerebral beta-amyloidosis. Science 2010, 330, 980–982. [CrossRef]
139. Eisele, Y.S.; Fritschi, S.K.; Hamaguchi, T.; Obermuller, U.; Fuger, P.; Skodras, A.; Schafer, C.; Odenthal, J.;
Heikenwalder, M.; Staufenbiel, M.; et al. Multiple factors contribute to the peripheral induction of cerebral
beta-amyloidosis. J. Neurosci. 2014, 34, 10264–10273. [CrossRef]
140. Eisele, Y.S.; Bolmont, T.; Heikenwalder, M.; Langer, F.; Jacobson, L.H.; Yan, Z.X.; Roth, K.; Aguzzi, A.;
Staufenbiel, M.; Walker, L.C.; et al. Induction of cerebral beta-amyloidosis: Intracerebral versus systemic
Abeta inoculation. Proc. Natl. Acad. Sci. USA 2009, 106, 12926–12931. [CrossRef]
141. Stohr, J.; Watts, J.C.; Mensinger, Z.L.; Oehler, A.; Grillo, S.K.; DeArmond, S.J.; Prusiner, S.B.; Giles, K. Purified
and synthetic Alzheimer’s amyloid beta (Abeta) prions. Proc. Natl. Acad. Sci. USA 2012, 109, 11025–11030.
[CrossRef]
142. Stohr, J.; Condello, C.; Watts, J.C.; Bloch, L.; Oehler, A.; Nick, M.; DeArmond, S.J.; Giles, K.; DeGrado, W.F.;
Prusiner, S.B. Distinct synthetic Abeta prion strains producing different amyloid deposits in bigenic mice.
Proc. Natl. Acad. Sci. USA 2014, 111, 10329–10334. [CrossRef]
143. Purro, S.A.; Farrow, M.A.; Linehan, J.; Nazari, T.; Thomas, D.X.; Chen, Z.; Mengel, D.; Saito, T.; Saido, T.;
Rudge, P.; et al. Transmission of amyloid-beta protein pathology from cadaveric pituitary growth hormone.
Nature 2018, 564, 415–419. [CrossRef]
144. Heuer, E.; Rosen, R.F.; Cintron, A.; Walker, L.C. Nonhuman primate models of Alzheimer-like cerebral
proteopathy. Curr. Pharm. Des. 2012, 18, 1159–1169. [CrossRef]
145. Jucker, M. The benefits and limitations of animal models for translational research in neurodegenerative
diseases. Nat. Med. 2010, 16, 1210–1214. [CrossRef]
146. Petkova, A.T.; Leapman, R.D.; Guo, Z.; Yau, W.M.; Mattson, M.P.; Tycko, R. Self-propagating, molecular-level
polymorphism in Alzheimer’s beta-amyloid fibrils. Science 2005, 307, 262–265. [CrossRef]
Viruses 2019, 11, 261 32 of 37
147. Qiang, W.; Yau, W.M.; Lu, J.X.; Collinge, J.; Tycko, R. Structural variation in amyloid-beta fibrils from
Alzheimer’s disease clinical subtypes. Nature 2017, 541, 217–221. [CrossRef]
148. Rosen, R.F.; Ciliax, B.J.; Wingo, T.S.; Gearing, M.; Dooyema, J.; Lah, J.J.; Ghiso, J.A.; LeVine, H., 3rd;
Walker, L.C. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer’s disease. Acta
Neuropathol. 2010, 119, 221–233. [CrossRef]
149. Binder, L.I.; Frankfurter, A.; Rebhun, L.I. The distribution of tau in the mammalian central nervous system. J.
Cell Biol. 1985, 101, 1371–1378. [CrossRef]
150. Dugger, B.N.; Whiteside, C.M.; Maarouf, C.L.; Walker, D.G.; Beach, T.G.; Sue, L.I.; Garcia, A.; Dunckley, T.;
Meechoovet, B.; Reiman, E.M.; et al. The Presence of Select Tau Species in Human Peripheral Tissues and
Their Relation to Alzheimer’s Disease. J. Alzheimers Dis. 2016, 51, 345–356. [CrossRef]
151. Kahlson, M.A.; Colodner, K.J. Glial Tau Pathology in Tauopathies: Functional Consequences. J. Exp. Neurosci.
2015, 9, 43–50. [CrossRef]
152. Buee, L.; Bussiere, T.; Buee-Scherrer, V.; Delacourte, A.; Hof, P.R. Tau protein isoforms, phosphorylation and
role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 2000, 33, 95–130. [CrossRef]
153. Andreadis, A.; Brown, W.M.; Kosik, K.S. Structure and novel exons of the human tau gene. Biochemistry 1992,
31, 10626–10633. [CrossRef]
154. Goedert, M.; Spillantini, M.G.; Jakes, R.; Rutherford, D.; Crowther, R.A. Multiple isoforms of human
microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer’s
disease. Neuron 1989, 3, 519–526. [CrossRef]
155. Liu, F.; Gong, C.X. Tau exon 10 alternative splicing and tauopathies. Mol. Neurodegener. 2008, 3, 8. [CrossRef]
156. Avila, J.; Jimenez, J.S.; Sayas, C.L.; Bolos, M.; Zabala, J.C.; Rivas, G.; Hernandez, F. Tau Structures. Front.
Aging Neurosci. 2016, 8, 262. [CrossRef]
157. Leterrier, J.F.; Liem, R.K.; Shelanski, M.L. Interactions between neurofilaments and microtubule-associated
proteins: A possible mechanism for intraorganellar bridging. J. Cell Biol. 1982, 95, 982–986. [CrossRef]
158. Rendon, A.; Jung, D.; Jancsik, V. Interaction of microtubules and microtubule-associated proteins (MAPs)
with rat brain mitochondria. Biochem. J. 1990, 269, 555–556. [CrossRef]
159. Chen, J.; Kanai, Y.; Cowan, N.J.; Hirokawa, N. Projection domains of MAP2 and tau determine spacings
between microtubules in dendrites and axons. Nature 1992, 360, 674–677. [CrossRef]
160. Lee, G.; Newman, S.T.; Gard, D.L.; Band, H.; Panchamoorthy, G. Tau interacts with src-family non-receptor
tyrosine kinases. J. Cell Sci. 1998, 111 Pt 21, 3167–3177.
161. Hwang, S.C.; Jhon, D.Y.; Bae, Y.S.; Kim, J.H.; Rhee, S.G. Activation of phospholipase C-gamma by the
concerted action of tau proteins and arachidonic acid. J. Biol. Chem. 1996, 271, 18342–18349. [CrossRef]
162. Drechsel, D.N.; Hyman, A.A.; Cobb, M.H.; Kirschner, M.W. Modulation of the dynamic instability of tubulin
assembly by the microtubule-associated protein tau. Mol. Biol. Cell 1992, 3, 1141–1154. [CrossRef]
163. Correas, I.; Padilla, R.; Avila, J. The tubulin-binding sequence of brain microtubule-associated proteins, tau
and MAP-2, is also involved in actin binding. Biochem. J. 1990, 269, 61–64. [CrossRef]
164. Griffith, L.M.; Pollard, T.D. The interaction of actin filaments with microtubules and microtubule-associated
proteins. J. Biol. Chem. 1982, 257, 9143–9151.
165. Carlier, M.F.; Simon, C.; Cassoly, R.; Pradel, L.A. Interaction between microtubule-associated protein tau and
spectrin. Biochimie 1984, 66, 305–311. [CrossRef]
166. Martin, L.; Latypova, X.; Terro, F. Post-translational modifications of tau protein: Implications for Alzheimer’s
disease. Neurochem. Int. 2011, 58, 458–471. [CrossRef]
167. Drewes, G.; Trinczek, B.; Illenberger, S.; Biernat, J.; Schmitt-Ulms, G.; Meyer, H.E.; Mandelkow, E.M.;
Mandelkow, E. Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel
protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the
Alzheimer-specific site serine 262. J. Biol. Chem. 1995, 270, 7679–7688. [CrossRef]
168. Eidenmuller, J.; Fath, T.; Maas, T.; Pool, M.; Sontag, E.; Brandt, R. Phosphorylation-mimicking glutamate
clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated
tau protein. Biochem. J. 2001, 357, 759–767. [CrossRef]
169. Liu, F.; Li, B.; Tung, E.J.; Grundke-Iqbal, I.; Iqbal, K.; Gong, C.X. Site-specific effects of tau phosphorylation
on its microtubule assembly activity and self-aggregation. Eur. J. Neurosci. 2007, 26, 3429–3436. [CrossRef]
Viruses 2019, 11, 261 33 of 37
170. Hoover, B.R.; Reed, M.N.; Su, J.; Penrod, R.D.; Kotilinek, L.A.; Grant, M.K.; Pitstick, R.; Carlson, G.A.;
Lanier, L.M.; Yuan, L.L.; et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction
independently of neurodegeneration. Neuron 2010, 68, 1067–1081. [CrossRef]
171. Dickey, C.A.; Kamal, A.; Lundgren, K.; Klosak, N.; Bailey, R.M.; Dunmore, J.; Ash, P.; Shoraka, S.;
Zlatkovic, J.; Eckman, C.B.; et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades
phosphorylated tau client proteins. J. Clin. Investig. 2007, 117, 648–658. [CrossRef]
172. Sergeant, N.; Delacourte, A.; Buee, L. Tau protein as a differential biomarker of tauopathies. Biochim. Biophys.
Acta 2005, 1739, 179–197. [CrossRef]
173. Falcon, B.; Zhang, W.; Schweighauser, M.; Murzin, A.G.; Vidal, R.; Garringer, H.J.; Ghetti, B.; Scheres, S.H.W.;
Goedert, M. Tau filaments from multiple cases of sporadic and inherited Alzheimer’s disease adopt a
common fold. Acta Neuropathol. 2018, 136, 699–708. [CrossRef] [PubMed]
174. Falcon, B.; Zhang, W.; Murzin, A.G.; Murshudov, G.; Garringer, H.J.; Vidal, R.; Crowther, R.A.; Ghetti, B.;
Scheres, S.H.W.; Goedert, M. Structures of filaments from Pick’s disease reveal a novel tau protein fold.
Nature 2018, 561, 137–140. [CrossRef] [PubMed]
175. Clavaguera, F.; Bolmont, T.; Crowther, R.A.; Abramowski, D.; Frank, S.; Probst, A.; Fraser, G.; Stalder, A.K.;
Beibel, M.; Staufenbiel, M.; et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat.
Cell Biol. 2009, 11, 909–913. [CrossRef]
176. Mirbaha, H.; Holmes, B.B.; Sanders, D.W.; Bieschke, J.; Diamond, M.I. Tau Trimers Are the Minimal
Propagation Unit Spontaneously Internalized to Seed Intracellular Aggregation. J. Biol. Chem. 2015, 290,
14893–14903. [CrossRef]
177. Mukrasch, M.D.; von Bergen, M.; Biernat, J.; Fischer, D.; Griesinger, C.; Mandelkow, E.; Zweckstetter, M. The
“jaws” of the tau-microtubule interaction. J. Biol. Chem. 2007, 282, 12230–12239. [CrossRef]
178. Clavaguera, F.; Akatsu, H.; Fraser, G.; Crowther, R.A.; Frank, S.; Hench, J.; Probst, A.; Winkler, D.T.;
Reichwald, J.; Staufenbiel, M.; et al. Brain homogenates from human tauopathies induce tau inclusions in
mouse brain. Proc. Natl. Acad. Sci. USA 2013, 110, 9535–9540. [CrossRef]
179. Falcon, B.; Cavallini, A.; Angers, R.; Glover, S.; Murray, T.K.; Barnham, L.; Jackson, S.; O’Neill, M.J.;
Isaacs, A.M.; Hutton, M.L.; et al. Conformation determines the seeding potencies of native and recombinant
Tau aggregates. J. Biol. Chem. 2015, 290, 1049–1065. [CrossRef] [PubMed]
180. Iba, M.; McBride, J.D.; Guo, J.L.; Zhang, B.; Trojanowski, J.Q.; Lee, V.M. Tau pathology spread in PS19 tau
transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC’s
afferent and efferent connections. Acta Neuropathol. 2015, 130, 349–362. [CrossRef] [PubMed]
181. Kaufman, S.K.; Sanders, D.W.; Thomas, T.L.; Ruchinskas, A.J.; Vaquer-Alicea, J.; Sharma, A.M.; Miller, T.M.;
Diamond, M.I. Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional
Vulnerability In Vivo. Neuron 2016, 92, 796–812. [CrossRef] [PubMed]
182. Rauch, J.N.; Chen, J.J.; Sorum, A.W.; Miller, G.M.; Sharf, T.; See, S.K.; Hsieh-Wilson, L.C.; Kampmann, M.;
Kosik, K.S. Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs). Sci.
Rep. 2018, 8, 6382. [CrossRef]
183. Wu, J.W.; Herman, M.; Liu, L.; Simoes, S.; Acker, C.M.; Figueroa, H.; Steinberg, J.I.; Margittai, M.; Kayed, R.;
Zurzolo, C.; et al. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and
retrogradely transported in neurons. J. Biol. Chem. 2013, 288, 1856–1870. [CrossRef]
184. Abounit, S.; Bousset, L.; Loria, F.; Zhu, S.; de Chaumont, F.; Pieri, L.; Olivo-Marin, J.C.; Melki, R.; Zurzolo, C.
Tunneling nanotubes spread fibrillar alpha-synuclein by intercellular trafficking of lysosomes. EMBO J. 2016,
35, 2120–2138. [CrossRef]
185. Tardivel, M.; Begard, S.; Bousset, L.; Dujardin, S.; Coens, A.; Melki, R.; Buee, L.; Colin, M. Tunneling nanotube
(TNT)-mediated neuron-to neuron transfer of pathological Tau protein assemblies. Acta Neuropathol. Commun.
2016, 4, 117. [CrossRef]
186. Ahmed, Z.; Cooper, J.; Murray, T.K.; Garn, K.; McNaughton, E.; Clarke, H.; Parhizkar, S.; Ward, M.A.;
Cavallini, A.; Jackson, S.; et al. A novel in vivo model of tau propagation with rapid and progressive
neurofibrillary tangle pathology: The pattern of spread is determined by connectivity, not proximity. Acta
Neuropathol. 2014, 127, 667–683. [CrossRef]
187. Dujardin, S.; Lecolle, K.; Caillierez, R.; Begard, S.; Zommer, N.; Lachaud, C.; Carrier, S.; Dufour, N.;
Auregan, G.; Winderickx, J.; et al. Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic
mechanism: Relevance to sporadic tauopathies. Acta Neuropathol. Commun. 2014, 2, 14. [CrossRef]
Viruses 2019, 11, 261 34 of 37
188. Peeraer, E.; Bottelbergs, A.; Van Kolen, K.; Stancu, I.C.; Vasconcelos, B.; Mahieu, M.; Duytschaever, H.; Ver
Donck, L.; Torremans, A.; Sluydts, E.; et al. Intracerebral injection of preformed synthetic tau fibrils initiates
widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiol. Dis. 2015, 73, 83–95.
[CrossRef]
189. De Calignon, A.; Polydoro, M.; Suarez-Calvet, M.; William, C.; Adamowicz, D.H.; Kopeikina, K.J.; Pitstick, R.;
Sahara, N.; Ashe, K.H.; Carlson, G.A.; et al. Propagation of tau pathology in a model of early Alzheimer’s
disease. Neuron 2012, 73, 685–697. [CrossRef]
190. Liu, L.; Drouet, V.; Wu, J.W.; Witter, M.P.; Small, S.A.; Clelland, C.; Duff, K. Trans-synaptic spread of tau
pathology in vivo. PLoS ONE 2012, 7, e31302. [CrossRef]
191. Asai, H.; Ikezu, S.; Tsunoda, S.; Medalla, M.; Luebke, J.; Haydar, T.; Wolozin, B.; Butovsky, O.; Kugler, S.;
Ikezu, T. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci.
2015, 18, 1584–1593. [CrossRef]
192. Siddiqua, A.; Margittai, M. Three- and four-repeat Tau coassemble into heterogeneous filaments: An
implication for Alzheimer disease. J. Biol. Chem. 2010, 285, 37920–37926. [CrossRef]
193. Dinkel, P.D.; Siddiqua, A.; Huynh, H.; Shah, M.; Margittai, M. Variations in filament conformation dictate
seeding barrier between three- and four-repeat tau. Biochemistry 2011, 50, 4330–4336. [CrossRef]
194. Weismiller, H.A.; Murphy, R.; Wei, G.; Ma, B.; Nussinov, R.; Margittai, M. Structural disorder in four-repeat
Tau fibrils reveals a new mechanism for barriers to cross-seeding of Tau isoforms. J. Biol. Chem. 2018, 293,
17336–17348. [CrossRef]
195. Fitzpatrick, A.W.P.; Falcon, B.; He, S.; Murzin, A.G.; Murshudov, G.; Garringer, H.J.; Crowther, R.A.; Ghetti, B.;
Goedert, M.; Scheres, S.H.W. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature 2017,
547, 185–190. [CrossRef]
196. Goedert, M.; Jakes, R. Mutations causing neurodegenerative tauopathies. Biochim. Biophys. Acta 2005, 1739,
240–250. [CrossRef]
197. Frost, B.; Ollesch, J.; Wille, H.; Diamond, M.I. Conformational diversity of wild-type Tau fibrils specified by
templated conformation change. J. Biol. Chem. 2009, 284, 3546–3551. [CrossRef]
198. Von Bergen, M.; Friedhoff, P.; Biernat, J.; Heberle, J.; Mandelkow, E.M.; Mandelkow, E. Assembly of tau
protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311))
forming beta structure. Proc. Natl. Acad. Sci. USA 2000, 97, 5129–5134. [CrossRef]
199. Aoyagi, H.; Hasegawa, M.; Tamaoka, A. Fibrillogenic nuclei composed of P301L mutant tau induce
elongation of P301L tau but not wild-type tau. J. Biol. Chem. 2007, 282, 20309–20318. [CrossRef]
200. Guo, J.L.; Narasimhan, S.; Changolkar, L.; He, Z.; Stieber, A.; Zhang, B.; Gathagan, R.J.; Iba, M.; McBride, J.D.;
Trojanowski, J.Q.; et al. Unique pathological tau conformers from Alzheimer’s brains transmit tau pathology
in nontransgenic mice. J. Exp. Med. 2016, 213, 2635–2654. [CrossRef]
201. Saijo, E.; Ghetti, B.; Zanusso, G.; Oblak, A.; Furman, J.L.; Diamond, M.I.; Kraus, A.; Caughey, B. Ultrasensitive
and selective detection of 3-repeat tau seeding activity in Pick disease brain and cerebrospinal fluid. Acta
Neuropathol. 2017, 133, 751–765. [CrossRef]
202. Narasimhan, S.; Guo, J.L.; Changolkar, L.; Stieber, A.; McBride, J.D.; Silva, L.V.; He, Z.; Zhang, B.;
Gathagan, R.J.; Trojanowski, J.Q.; et al. Pathological Tau Strains from Human Brains Recapitulate the
Diversity of Tauopathies in Nontransgenic Mouse Brain. J. Neurosci. Off. J. Soc. Neurosci. 2017, 37,
11406–11423. [CrossRef]
203. Emamzadeh, F.N. Alpha-synuclein structure, functions, and interactions. J. Res. Med. Sci. 2016, 21, 29.
[CrossRef]
204. Sode, K.; Ochiai, S.; Kobayashi, N.; Usuzaka, E. Effect of reparation of repeat sequences in the human
alpha-synuclein on fibrillation ability. Int. J. Biol. Sci. 2006, 3, 1–7.
205. Giasson, B.I.; Murray, I.V.; Trojanowski, J.Q.; Lee, V.M. A hydrophobic stretch of 12 amino acid residues in the
middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 2001, 276, 2380–2386. [CrossRef]
206. Bertoncini, C.W.; Jung, Y.S.; Fernandez, C.O.; Hoyer, W.; Griesinger, C.; Jovin, T.M.; Zweckstetter, M. Release
of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc.
Natl. Acad. Sci. USA 2005, 102, 1430–1435. [CrossRef]
Viruses 2019, 11, 261 35 of 37
207. Li, W.; West, N.; Colla, E.; Pletnikova, O.; Troncoso, J.C.; Marsh, L.; Dawson, T.M.; Jakala, P.; Hartmann, T.;
Price, D.L.; et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular
process and is enhanced by the familial Parkinson’s disease-linked mutations. Proc. Natl. Acad. Sci. USA
2005, 102, 2162–2167. [CrossRef]
208. Kim, T.D.; Choi, E.; Rhim, H.; Paik, S.R.; Yang, C.H. Alpha-synuclein has structural and functional similarities
to small heat shock proteins. Biochem. Biophys. Res. Commun. 2004, 324, 1352–1359. [CrossRef]
209. Baldwin, A.J.; Knowles, T.P.; Tartaglia, G.G.; Fitzpatrick, A.W.; Devlin, G.L.; Shammas, S.L.; Waudby, C.A.;
Mossuto, M.F.; Meehan, S.; Gras, S.L.; et al. Metastability of native proteins and the phenomenon of amyloid
formation. J. Am. Chem. Soc. 2011, 133, 14160–14163. [CrossRef]
210. Savica, R.; Grossardt, B.R.; Bower, J.H.; Ahlskog, J.E.; Rocca, W.A. Incidence and pathology of
synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol. 2013, 70, 859–866. [CrossRef]
211. Marti, M.J.; Tolosa, E.; Campdelacreu, J. Clinical overview of the synucleinopathies. Mov. Disord. 2003, 18
(Suppl. 6), 21–27. [CrossRef]
212. Beitz, J.M. Parkinson’s disease: A review. Front. Biosci. (Sch. Ed.) 2014, 6, 65–74. [CrossRef]
213. Dickson, D.W. Parkinson’s disease and parkinsonism: Neuropathology. Cold Spring Harb. Perspect. Med.
2012, 2, a009258. [CrossRef] [PubMed]
214. Donaghy, P.C.; McKeith, I.G. The clinical characteristics of dementia with Lewy bodies and a consideration
of prodromal diagnosis. Alzheimers Res. 2014, 6, 46. [CrossRef] [PubMed]
215. Stefanova, N.; Bucke, P.; Duerr, S.; Wenning, G.K. Multiple system atrophy: An update. Lancet Neurol. 2009,
8, 1172–1178. [CrossRef]
216. Kordower, J.H.; Chu, Y.; Hauser, R.A.; Freeman, T.B.; Olanow, C.W. Lewy body-like pathology in long-term
embryonic nigral transplants in Parkinson’s disease. Nat. Med. 2008, 14, 504–506. [CrossRef]
217. Li, J.Y.; Englund, E.; Holton, J.L.; Soulet, D.; Hagell, P.; Lees, A.J.; Lashley, T.; Quinn, N.P.; Rehncrona, S.;
Bjorklund, A.; et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft
disease propagation. Nat. Med. 2008, 14, 501–503. [CrossRef] [PubMed]
218. Desplats, P.; Lee, H.J.; Bae, E.J.; Patrick, C.; Rockenstein, E.; Crews, L.; Spencer, B.; Masliah, E.; Lee, S.J.
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein.
Proc. Natl. Acad. Sci. USA 2009, 106, 13010–13015. [CrossRef] [PubMed]
219. Watts, J.C.; Giles, K.; Oehler, A.; Middleton, L.; Dexter, D.T.; Gentleman, S.M.; DeArmond, S.J.; Prusiner, S.B.
Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl. Acad. Sci. USA 2013, 110,
19555–19560. [CrossRef]
220. Luk, K.C.; Kehm, V.; Carroll, J.; Zhang, B.; O’Brien, P.; Trojanowski, J.Q.; Lee, V.M. Pathological
alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science
2012, 338, 949–953. [CrossRef]
221. Luk, K.C.; Kehm, V.M.; Zhang, B.; O’Brien, P.; Trojanowski, J.Q.; Lee, V.M. Intracerebral inoculation of
pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in
mice. J. Exp. Med. 2012, 209, 975–986. [CrossRef]
222. Luk, K.C.; Song, C.; O’Brien, P.; Stieber, A.; Branch, J.R.; Brunden, K.R.; Trojanowski, J.Q.; Lee, V.M.
Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured
cells. Proc. Natl. Acad. Sci. USA 2009, 106, 20051–20056. [CrossRef] [PubMed]
223. Masuda-Suzukake, M.; Nonaka, T.; Hosokawa, M.; Oikawa, T.; Arai, T.; Akiyama, H.; Mann, D.M.;
Hasegawa, M. Prion-like spreading of pathological alpha-synuclein in brain. Brain J. Neurol. 2013, 136,
1128–1138. [CrossRef] [PubMed]
224. Sacino, A.N.; Brooks, M.; McGarvey, N.H.; McKinney, A.B.; Thomas, M.A.; Levites, Y.; Ran, Y.; Golde, T.E.;
Giasson, B.I. Induction of CNS alpha-synuclein pathology by fibrillar and non-amyloidogenic recombinant
alpha-synuclein. Acta Neuropathol. Commun. 2013, 1, 38. [CrossRef]
225. Volpicelli-Daley, L.A.; Luk, K.C.; Patel, T.P.; Tanik, S.A.; Riddle, D.M.; Stieber, A.; Meaney, D.F.;
Trojanowski, J.Q.; Lee, V.M. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to
synaptic dysfunction and neuron death. Neuron 2011, 72, 57–71. [CrossRef]
226. Aulic, S.; Le, T.T.; Moda, F.; Abounit, S.; Corvaglia, S.; Casalis, L.; Gustincich, S.; Zurzolo, C.; Tagliavini, F.;
Legname, G. Defined alpha-synuclein prion-like molecular assemblies spreading in cell culture. BMC
Neurosci. 2014, 15, 69. [CrossRef] [PubMed]
Viruses 2019, 11, 261 36 of 37
227. Recasens, A.; Dehay, B.; Bove, J.; Carballo-Carbajal, I.; Dovero, S.; Perez-Villalba, A.; Fernagut, P.O.; Blesa, J.;
Parent, A.; Perier, C.; et al. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein
pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 2014, 75, 351–362. [CrossRef]
[PubMed]
228. Brundin, P.; Melki, R. Prying into the Prion Hypothesis for Parkinson’s Disease. J. Neurosci. 2017, 37,
9808–9818. [CrossRef] [PubMed]
229. Aguzzi, A.; Lakkaraju, A.K.K. Cell Biology of Prions and Prionoids: A Status Report. Trends Cell Biol. 2016,
26, 40–51. [CrossRef]
230. Tamguney, G.; Korczyn, A.D. A critical review of the prion hypothesis of human synucleinopathies. Cell
Tissue Res. 2018, 373, 213–220. [CrossRef]
231. Nonaka, T.; Watanabe, S.T.; Iwatsubo, T.; Hasegawa, M. Seeded aggregation and toxicity of α-synuclein and
tau: Cellular models of neurodegenerative diseases. J. Biol. Chem. 2010, 285, 34885–34898. [CrossRef]
232. Bousset, L.; Pieri, L.; Ruiz-Arlandis, G.; Gath, J.; Jensen, P.H.; Habenstein, B.; Madiona, K.; Olieric, V.;
Bockmann, A.; Meier, B.H.; et al. Structural and functional characterization of two alpha-synuclein strains.
Nat. Commun. 2013, 4, 2575. [CrossRef]
233. Fujiwara, H.; Hasegawa, M.; Dohmae, N.; Kawashima, A.; Masliah, E.; Goldberg, M.S.; Shen, J.; Takio, K.;
Iwatsubo, T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4, 160–164.
[CrossRef]
234. Ma, M.R.; Hu, Z.W.; Zhao, Y.F.; Chen, Y.X.; Li, Y.M. Phosphorylation induces distinct alpha-synuclein strain
formation. Sci. Rep. 2016, 6, 37130. [CrossRef]
235. Peng, C.; Gathagan, R.J.; Covell, D.J.; Medellin, C.; Stieber, A.; Robinson, J.L.; Zhang, B.; Pitkin, R.M.;
Olufemi, M.F.; Luk, K.C.; et al. Cellular milieu imparts distinct pathological alpha-synuclein strains in
alpha-synucleinopathies. Nature 2018, 557, 558–563. [CrossRef]
236. Arai, T.; Hasegawa, M.; Akiyama, H.; Ikeda, K.; Nonaka, T.; Mori, H.; Mann, D.; Tsuchiya, K.; Yoshida, M.;
Hashizume, Y.; et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal
lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006, 351, 602–611.
[CrossRef]
237. Neumann, M.; Sampathu, D.M.; Kwong, L.K.; Truax, A.C.; Micsenyi, M.C.; Chou, T.T.; Bruce, J.; Schuck, T.;
Grossman, M.; Clark, C.M.; et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and
amyotrophic lateral sclerosis. Science 2006, 314, 130–133. [CrossRef]
238. Hasegawa, M.; Arai, T.; Nonaka, T.; Kametani, F.; Yoshida, M.; Hashizume, Y.; Beach, T.G.; Buratti, E.;
Baralle, F.; Morita, M.; et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic
lateral sclerosis. Ann. Neurol. 2008, 64, 60–70. [CrossRef]
239. Gregory, R.I.; Yan, K.P.; Amuthan, G.; Chendrimada, T.; Doratotaj, B.; Cooch, N.; Shiekhattar, R. The
Microprocessor complex mediates the genesis of microRNAs. Nature 2004, 432, 235–240. [CrossRef]
240. Sreedharan, J.; Blair, I.P.; Tripathi, V.B.; Hu, X.; Vance, C.; Rogelj, B.; Ackerley, S.; Durnall, J.C.; Williams, K.L.;
Buratti, E.; et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319,
1668–1672. [CrossRef]
241. Lagier-Tourenne, C.; Polymenidou, M.; Cleveland, D.W. TDP-43 and FUS/TLS: Emerging roles in RNA
processing and neurodegeneration. Hum. Mol. Genet. 2010, 19, R46–R64. [CrossRef]
242. Casafont, I.; Bengoechea, R.; Tapia, O.; Berciano, M.T.; Lafarga, M. TDP-43 localizes in mRNA transcription
and processing sites in mammalian neurons. J. Struct. Biol. 2009, 167, 235–241. [CrossRef]
243. Wu, L.S.; Cheng, W.C.; Hou, S.C.; Yan, Y.T.; Jiang, S.T.; Shen, C.K. TDP-43, a neuro-pathosignature factor, is
essential for early mouse embryogenesis. Genesis 2010, 48, 56–62. [CrossRef]
244. Kraemer, B.C.; Schuck, T.; Wheeler, J.M.; Robinson, L.C.; Trojanowski, J.Q.; Lee, V.M.; Schellenberg, G.D. Loss
of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol.
2010, 119, 409–419. [CrossRef]
245. Sephton, C.F.; Good, S.K.; Atkin, S.; Dewey, C.M.; Mayer, P., 3rd; Herz, J.; Yu, G. TDP-43 is a developmentally
regulated protein essential for early embryonic development. J. Biol. Chem. 2010, 285, 6826–6834. [CrossRef]
246. Nonaka, T.; Hasegawa, M. TDP-43 Prions. Cold Spring Harb. Perspect. Med. 2018, 8, a024463. [CrossRef]
247. Daoud, H.; Valdmanis, P.N.; Kabashi, E.; Dion, P.; Dupre, N.; Camu, W.; Meininger, V.; Rouleau, G.A.
Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. J. Med. Genet. 2009, 46,
112–114. [CrossRef]
Viruses 2019, 11, 261 37 of 37
248. Kabashi, E.; Valdmanis, P.N.; Dion, P.; Spiegelman, D.; McConkey, B.J.; Vande Velde, C.; Bouchard, J.P.;
Lacomblez, L.; Pochigaeva, K.; Salachas, F.; et al. TARDBP mutations in individuals with sporadic and
familial amyotrophic lateral sclerosis. Nat. Genet. 2008, 40, 572–574. [CrossRef]
249. Rutherford, N.J.; Zhang, Y.J.; Baker, M.; Gass, J.M.; Finch, N.A.; Xu, Y.F.; Stewart, H.; Kelley, B.J.; Kuntz, K.;
Crook, R.J.; et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral
sclerosis. PLoS Genet. 2008, 4, e1000193. [CrossRef]
250. Tsermentseli, S.; Leigh, P.N.; Goldstein, L.H. The anatomy of cognitive impairment in amyotrophic lateral
sclerosis: More than frontal lobe dysfunction. Cortex 2012, 48, 166–182. [CrossRef]
251. Mackenzie, I.R.; Neumann, M.; Baborie, A.; Sampathu, D.M.; Du Plessis, D.; Jaros, E.; Perry, R.H.;
Trojanowski, J.Q.; Mann, D.M.; Lee, V.M. A harmonized classification system for FTLD-TDP pathology. Acta
Neuropathol. 2011, 122, 111–113. [CrossRef]
252. Lee, E.B.; Porta, S.; Michael Baer, G.; Xu, Y.; Suh, E.; Kwong, L.K.; Elman, L.; Grossman, M.; Lee, V.M.;
Irwin, D.J.; et al. Expansion of the classification of FTLD-TDP: Distinct pathology associated with rapidly
progressive frontotemporal degeneration. Acta Neuropathol. 2017, 134, 65–78. [CrossRef]
253. Furukawa, Y.; Kaneko, K.; Watanabe, S.; Yamanaka, K.; Nukina, N. A seeding reaction recapitulates
intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding
protein-43 inclusions. J. Biol. Chem. 2011, 286, 18664–18672. [CrossRef] [PubMed]
254. Jiang, L.L.; Che, M.X.; Zhao, J.; Zhou, C.J.; Xie, M.Y.; Li, H.Y.; He, J.H.; Hu, H.Y. Structural transformation of
the amyloidogenic core region of TDP-43 protein initiates its aggregation and cytoplasmic inclusion. J. Biol.
Chem. 2013, 288, 19614–19624. [CrossRef] [PubMed]
255. Johnson, B.S.; Snead, D.; Lee, J.J.; McCaffery, J.M.; Shorter, J.; Gitler, A.D. TDP-43 is intrinsically
aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase
toxicity. J. Biol. Chem. 2009, 284, 20329–20339. [CrossRef] [PubMed]
256. Porta, S.; Xu, Y.; Restrepo, C.R.; Kwong, L.K.; Zhang, B.; Brown, H.J.; Lee, E.B.; Trojanowski, J.Q.; Lee, V.M.
Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43
pathology in vivo. Nat. Commun. 2018, 9, 4220. [CrossRef] [PubMed]
257. Kwong, L.K.; Uryu, K.; Trojanowski, J.Q.; Lee, V.M. TDP-43 proteinopathies: Neurodegenerative protein
misfolding diseases without amyloidosis. Neurosignals 2008, 16, 41–51. [CrossRef] [PubMed]
258. Neumann, M.; Kwong, L.K.; Sampathu, D.M.; Trojanowski, J.Q.; Lee, V.M. TDP-43 proteinopathy in
frontotemporal lobar degeneration and amyotrophic lateral sclerosis: Protein misfolding diseases without
amyloidosis. Arch. Neurol. 2007, 64, 1388–1394. [CrossRef] [PubMed]
259. Robinson, J.L.; Geser, F.; Stieber, A.; Umoh, M.; Kwong, L.K.; Van Deerlin, V.M.; Lee, V.M.; Trojanowski, J.Q.
TDP-43 skeins show properties of amyloid in a subset of ALS cases. Acta Neuropathol. 2013, 125, 121–131.
[CrossRef]
260. Bigio, E.H.; Wu, J.Y.; Deng, H.X.; Bit-Ivan, E.N.; Mao, Q.; Ganti, R.; Peterson, M.; Siddique, N.; Geula, C.;
Siddique, T.; et al. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP)
and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties
of amyloid. Acta Neuropathol. 2013, 125, 463–465. [CrossRef]
261. Nonaka, T.; Masuda-Suzukake, M.; Arai, T.; Hasegawa, Y.; Akatsu, H.; Obi, T.; Yoshida, M.; Murayama, S.;
Mann, D.M.; Akiyama, H.; et al. Prion-like properties of pathological TDP-43 aggregates from diseased
brains. Cell Rep. 2013, 4, 124–134. [CrossRef]
262. Smethurst, P.; Newcombe, J.; Troakes, C.; Simone, R.; Chen, Y.R.; Patani, R.; Sidle, K. In vitro prion-like
behaviour of TDP-43 in ALS. Neurobiol. Dis. 2016, 96, 236–247. [CrossRef]
263. Strong, M.J.; Yang, W. The frontotemporal syndromes of ALS. Clinicopathological correlates. J. Mol. Neurosci.
2011, 45, 648–655. [CrossRef]
264. Shimonaka, S.; Nonaka, T.; Suzuki, G.; Hisanaga, S.; Hasegawa, M. Templated Aggregation of TAR
DNA-binding Protein of 43 kDa (TDP-43) by Seeding with TDP-43 Peptide Fibrils. J. Biol. Chem. 2016, 291,
8896–8907. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
